<SEC-DOCUMENT>0001104659-25-093436.txt : 20250925
<SEC-HEADER>0001104659-25-093436.hdr.sgml : 20250925
<ACCEPTANCE-DATETIME>20250925172328
ACCESSION NUMBER:		0001104659-25-093436
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20250924
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250925
DATE AS OF CHANGE:		20250925

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immuneering Corp
		CENTRAL INDEX KEY:			0001790340
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40675
		FILM NUMBER:		251344807

	BUSINESS ADDRESS:	
		STREET 1:		245 MAIN STREET, SECOND FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		617-500-8080

	MAIL ADDRESS:	
		STREET 1:		245 MAIN STREET, SECOND FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2526946d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:IMRX="http://immuneering.com/20250924">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_033_IMRX_immuneering.com_20250924 -->
<!-- Field: Set; Name: xdx; ID: xdx_04D_20250924_20250924 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DEntityCentralIndexKey_0001790340 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-09-24" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-09-24" id="Fact000004" name="dei:EntityCentralIndexKey">0001790340</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="imrx-20250924.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-09-24">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-24</xbrli:startDate>
        <xbrli:endDate>2025-09-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0"></p>

<p style="margin: 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 20%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM&#160;<span id="xdx_90F_edei--DocumentType_c20250924__20250924_zI6hOyX3EcV4"><ix:nonNumeric contextRef="AsOf2025-09-24" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 20%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section&#160;13 or 15(d)&#160;of</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of report (Date of earliest event reported):
<span id="xdx_904_edei--DocumentPeriodEndDate_c20250924__20250924_zsLKxD7QN7m7"><ix:nonNumeric contextRef="AsOf2025-09-24" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">September 24, 2025</ix:nonNumeric></span></b></p>

<p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 20%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_90E_edei--EntityRegistrantName_c20250924__20250924_zho3HVDKqAtk"><b><ix:nonNumeric contextRef="AsOf2025-09-24" id="Fact000011" name="dei:EntityRegistrantName">Immuneering
Corporation</ix:nonNumeric></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact name of Registrant as Specified in its
Charter)</b></p>

<p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 20%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 34%; padding-right: 2.65pt; padding-left: 2.65pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_901_edei--EntityIncorporationStateCountryCode_c20250924__20250924_zfEDYujz5xJa"><ix:nonNumeric contextRef="AsOf2025-09-24" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="width: 32%; padding-right: 2.65pt; padding-left: 2.65pt; text-align: center"><span id="xdx_905_edei--EntityFileNumber_c20250924__20250924_zfqDfeTFVenl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="AsOf2025-09-24" id="Fact000013" name="dei:EntityFileNumber">001-40675</ix:nonNumeric></b></span></td>
    <td style="width: 34%; padding-right: 2.65pt; padding-left: 2.65pt; text-align: center"><span id="xdx_902_edei--EntityTaxIdentificationNumber_c20250924__20250924_zuEvukXkBDNc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="AsOf2025-09-24" id="Fact000014" name="dei:EntityTaxIdentificationNumber">26-1976972</ix:nonNumeric></b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-right: 2.65pt; padding-left: 2.65pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(State
    or other jurisdiction</b></span><span style="font-size: 10pt"><br/>
    <b>of incorporation or organization)</b></span></td>
    <td style="padding-right: 2.65pt; padding-left: 2.65pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Commission</b></span><span style="font-size: 10pt"><br/>
    <b>File Number)</b></span></td>
    <td style="padding-right: 2.65pt; padding-left: 2.65pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(I.R.S.
    Employer</b></span><span style="font-size: 10pt"><br/>
    <b>Identification No.)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_908_edei--EntityAddressAddressLine1_c20250924__20250924_zSznXR5dj9Ya"><b><ix:nonNumeric contextRef="AsOf2025-09-24" id="Fact000015" name="dei:EntityAddressAddressLine1">245
Main St.</ix:nonNumeric></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_909_edei--EntityAddressAddressLine2_c20250924__20250924_zz4sLdl3KTVe"><b><ix:nonNumeric contextRef="AsOf2025-09-24" id="Fact000016" name="dei:EntityAddressAddressLine2">Second
Floor</ix:nonNumeric></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_90B_edei--EntityAddressCityOrTown_c20250924__20250924_zseCz3txZ4D"><b><ix:nonNumeric contextRef="AsOf2025-09-24" id="Fact000017" name="dei:EntityAddressCityOrTown">Cambridge</ix:nonNumeric></b></span><b>,
<span id="xdx_90E_edei--EntityAddressStateOrProvince_c20250924__20250924_z7zz8pWY3EEb"><ix:nonNumeric contextRef="AsOf2025-09-24" id="Fact000018" name="dei:EntityAddressStateOrProvince">MA</ix:nonNumeric></span></b><b> <span id="xdx_905_edei--EntityAddressPostalZipCode_c20250924__20250924_zhRMKOBmCbl2"><ix:nonNumeric contextRef="AsOf2025-09-24" id="Fact000019" name="dei:EntityAddressPostalZipCode">02142</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Address of principal executive offices) (Zip
Code)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_900_edei--CityAreaCode_c20250924__20250924_zzu5X5vyex8k"><ix:nonNumeric contextRef="AsOf2025-09-24" id="Fact000020" name="dei:CityAreaCode">617</ix:nonNumeric></span></b><b>)
<span id="xdx_901_edei--LocalPhoneNumber_c20250924__20250924_ztVU6d9Qhdwg"><ix:nonNumeric contextRef="AsOf2025-09-24" id="Fact000021" name="dei:LocalPhoneNumber">500-8080</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Registrant&#8217;s telephone number, include
area code)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>N/A</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Former Name or Former Address, if Changed
Since Last Report)</b></p>

<p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 20%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Check the appropriate box below if the Form&#160;8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 2pt; width: 5%; text-align: justify"><span id="xdx_904_edei--WrittenCommunications_c20250924__20250924_zyBMWh3bboRk" style="font-family: Wingdings; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-09-24" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></td>
    <td style="padding-bottom: 2pt; width: 95%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 2pt; text-align: justify"><span id="xdx_900_edei--SolicitingMaterial_c20250924__20250924_zxZzg9lHvtrc" style="font-family: Wingdings; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-09-24" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></td>
    <td style="padding-bottom: 2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 2pt; text-align: justify"><span id="xdx_90D_edei--PreCommencementTenderOffer_c20250924__20250924_zQQMsQOaHPwb" style="font-family: Wingdings; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-09-24" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></td>
    <td style="padding-bottom: 2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 2pt; text-align: justify"><span id="xdx_90D_edei--PreCommencementIssuerTenderOffer_c20250924__20250924_zDR5db4GCZnb" style="font-family: Wingdings; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-09-24" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></td>
    <td style="padding-bottom: 2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="5" style="padding-right: 2.65pt; padding-left: 2.65pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
    registered pursuant to Section&#160;12(b)&#160;of the Act:</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="5" style="padding-right: 2.65pt; padding-left: 2.65pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 34%; padding-right: 2.65pt; padding-left: 2.65pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Title
    of each class</span></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 28%; padding-right: 2.65pt; padding-left: 2.65pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Trading
    Symbol(s)</span></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="white-space: nowrap; width: 34%; padding-right: 2.65pt; padding-left: 2.65pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Name
    of each exchange on which registered</span></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; padding-right: 2.65pt; padding-left: 2.65pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_90E_edei--Security12bTitle_c20250924__20250924_zcOyGIiU15Wa"><ix:nonNumeric contextRef="AsOf2025-09-24" id="Fact000026" name="dei:Security12bTitle">Class
                                            A Common Stock,  par value $0.001 per share</ix:nonNumeric></span></p></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="white-space: nowrap; vertical-align: top; padding-right: 2.65pt; padding-left: 2.65pt; text-align: center"><span id="xdx_904_edei--TradingSymbol_c20250924__20250924_z3C5BJyQHQC" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-09-24" id="Fact000027" name="dei:TradingSymbol">IMRX</ix:nonNumeric></span></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="white-space: nowrap; vertical-align: top; padding-right: 2.65pt; padding-left: 2.65pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--SecurityExchangeName_c20250924__20250924_zjC0MJwtWLAb"><ix:nonNumeric contextRef="AsOf2025-09-24" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">The Nasdaq Global Market</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Indicate by check mark whether the registrant is
an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2
of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company&#160;&#160;</span><span id="xdx_900_edei--EntityEmergingGrowthCompany_c20250924__20250924_z8gprrvXEaaj" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2025-09-24" format="ixt:booleantrue" id="Fact000029" name="dei:EntityEmergingGrowthCompany">x</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;&#160;<span id="xdx_90D_edei--EntityExTransitionPeriod_c20250924__20250924_z0vbCbOuI6x3" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2025-09-24" format="ixt:booleanfalse" id="Fact000030" name="dei:EntityExTransitionPeriod">&#168;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 1.01. Entry into a Material Definitive Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 24, 2025, Immuneering Corporation (the &#8220;Company&#8221;)
entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with Leerink Partners LLC and Oppenheimer &amp; Co.
Inc., as underwriters (the &#8220;Underwriters&#8221;), in connection with the public offering, issuance and sale by the Company of 18,959,914
shares of the Company&#8217;s Class A common stock, at a public offering price of $9.23 per share, pursuant to an effective shelf registration
statement on Form S-3 (Registration No. 333-289589) and a related prospectus supplement filed with the Securities and Exchange Commission
(the &#8220;Offering&#8221;). In addition, under the terms of the Underwriting Agreement, the Company granted the Underwriters an option,
exercisable for a period of 30 days, to purchase up to an additional 2,843,987 shares of Class A common stock from the Company, less underwriting
discounts and commissions. All of the shares of Class A common stock to be sold in the Offering are being sold by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, as previously disclosed by the Company in a Current
Report on Form 8-K filed with the Securities and Exchange Commission on September 24, 2025, the Company entered into a securities
purchase agreement, dated September 24, 2025 (the &#8220;Purchase Agreement&#8221;), with Aventis Inc. (the &#8220;Investor&#8221;),
a wholly owned subsidiary of Sanofi, a French soci&#233;t&#233; anonyme, pursuant to which the Company, in a private placement
transaction (the &#8220;Private Placement&#8221;), agreed to issue and sell to the Investor $25.0 million of shares of Class A
common stock (or in certain circumstances in lieu of Class A common stock, shares of the Company&#8217;s non-voting Class B common
stock), subject to and contingent upon the closing of a firm commitment underwritten public offering of Class A common stock by the
Company that results in gross proceeds to the Company of at least $75.0 million and the pricing of which is publicly announced in a
press release issued by the Company on or before September 26, 2025 (a &#8220;Qualified Public Offering&#8221;). Pursuant to the
Purchase Agreement, the price per share in the Private Placement will be the price per share of Class A common stock to the public
in the Qualified Public Offering. Under the terms of the Purchase Agreement, the Offering constitutes a Qualified Public Offering.
Accordingly, pursuant to the Purchase Agreement, subject to the closing of the Offering and the other conditions set forth therein
the Investor has agreed to purchase from the Company, and the Company has agreed to issue and sell to the Investor, an aggregate of
2,708,559 shares of Class A common stock at the closing of the Private Placement. The closing of the Private Placement is contingent upon the
closing of the Offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The closing of the Offering and the closing of the Private Placement
are expected to occur concurrently on or about September 26, 2025, subject to the satisfaction of customary closing conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The
Company expects to receive net proceeds from the Offering of approximately $164.1 million, after deducting underwriting discounts
and commissions and estimated offering expenses payable by the Company, and excluding any exercise of the Underwriters' option to purchase additional shares. In addition, the Company expects to receive net proceeds
from the Private Placement of approximately $23.3 million, after deducting estimated private placement fees payable by the Company. The Company intends to use the net proceeds of
the Offering and the Private Placement to advance the preclinical and clinical development of its product candidates and for working
capital and other general corporate purposes. Based on its current business plans, the Company believes that its cash and cash
equivalents and marketable securities, together with the net proceeds from the Offering and the Private Placement (and excluding net proceeds from any exercise of the Underwriters' option to purchase additional shares of our common stock), will be
sufficient to fund its development activities and other operations into 2029.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Underwriting Agreement contains customary representations, warranties
and covenants by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including
for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. The representations,
warranties and covenants contained in the Underwriting Agreement were made solely for the benefit of the parties thereto and may be subject
to limitations agreed upon by the contracting parties. Accordingly, the Underwriting Agreement is incorporated herein by reference only
to provide investors with information regarding the terms of the Underwriting Agreement and not to provide investors with any other factual
information regarding the Company or its business, and should be read in conjunction with the disclosures in the Company&#8217;s periodic
reports and other filings with the Securities and Exchange Commission.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The foregoing description of the Underwriting Agreement is not complete
and is qualified in its entirety by reference to the full text of the Underwriting Agreement, a copy of which is filed as Exhibit 1.1
to this report and is incorporated by reference herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A copy of the opinion of Latham &amp; Watkins LLP relating to the legality
of the issuance and sale of the shares of Class A common stock in the Offering is attached as Exhibit 5.1 to this report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 8.01. Other Events.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 13, 2025, the Company entered into an equity
distribution agreement with Piper Sandler &amp; Co. relating to the sale of shares of the Company's Class A common stock having a
maximum aggregate offering price of up to $100,000,000 from time to time pursuant to at-the-market transactions (the "ATM Program").
As of the date of this report, the Company has not sold any shares under the ATM Program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the Offering, the Company (i) reduced the
maximum aggregate offering price for sales of shares pursuant to at-the-market transactions under the ATM Program by $1,250,007 (the
"Reduced Amount"), resulting in a new maximum aggregate offering price of up to $98,749,993 under the ATM Program, and (ii)
suspended the ATM Program and terminated the continuous offering under the ATM Program, in each case, as to the Reduced Amount.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Forward-Looking Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Current Report on Form 8-K (this &#8220;Current Report&#8221;)
contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained
in this Current Report that do not relate to matters of historical fact should be considered forward-looking statements, including, without
limitation, statements regarding the consummation of the Offering and the Private Placement, the terms of the Offering and the Private
Placement, the anticipated use of the net proceeds from the Offering and the Private Placement, the anticipated net proceeds from the
Offering and the Private Placement and the Company&#8217;s projected cash runway. These forward-looking statements are based only on the
Company&#8217;s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors
that could cause actual results to differ include, but are not limited to, the important factors discussed under the caption &#8220;Risk
Factors&#8221; in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024 and filed with the U.S. Securities
and Exchange Commission (the &#8220;SEC&#8221;) on March 20, 2025, the Company&#8217;s Quarterly Reports on Form 10-K for the quarterly
periods ended March 31, 2025 and June 30, 2025 and filed with the SEC on May 5, 2025 and August 13, 2025, respectively, and the Company&#8217;s
other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements
made in this Current Report. Any such forward-looking statements represent management&#8217;s estimates as of the date of this Current
Report. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation
to do so, even if subsequent events cause the Company&#8217;s views to change. These forward-looking statements should not be relied upon
as representing the Company&#8217;s views as of any date subsequent to the date of this Current Report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 9.01. Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 10%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit <br/>
No.</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 89%; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; font-size: 10pt"><a href="tm2526946d1_ex1-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt"><a href="tm2526946d1_ex1-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting Agreement, dated as of September 24, 2025, by and between Immuneering Corporation and Leerink Partners LLC and Oppenheimer &amp; Co. Inc.</span></a></td></tr>
  <tr>
    <td style="vertical-align: top; font-size: 10pt"><a href="tm2526946d1_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</span></a></td>
    <td style="vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt"><a href="tm2526946d1_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Latham &amp; Watkins LLP.</span></a></td></tr>
  <tr>
    <td style="vertical-align: top; font-size: 10pt"><a href="tm2526946d1_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></a></td>
    <td style="vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt"><a href="tm2526946d1_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Latham &amp; Watkins LLP (included in Exhibit 5.1).</span></a></td></tr>
  <tr>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (embedded within the inline XBRL document).</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%">&#160;</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Immuneering Corporation</b>&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 52%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 45%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: September 25, 2025</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Benjamin J. Zeskind</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benjamin J. Zeskind, Ph.D.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Co-Founder, President, Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%">&#160;</td><td style="width: 33%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&#160;</p>


<!-- eJxFjd0KwjAMhZ9g7xB6LW4d+MPudKiIU2SIeFtclOLWjLTq9ki+pd2GGAIhOefLEWIkNrTWJTJclnkGJ6zqUjmEHG/IaK7oHel2l4CfOd61dayM69cfmJJn0DPTsVT+3jtf2mKRQDQPYxnGE4hkImew2Iug01MyN12gcVqVoEwBR6aaNTrF7fDhpBoyVLV90hnZajIJyHE0yB+IIxnDgV7qTfywkGWpCEZ9BWLD9Ky9a9U4NB0JqxIrH2cH+t/BF8IsSkw= -->
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KwjAMhZ9g7xB6PXSrP+DudEwRp8gQ8ba6KMWtGWn9eyTf0rohhkBIzvlyhAjFgua6QobDrMhhh3VTKYdQ4BkZzQm9I12uEvCzwIu2jpVx7foDU/IMembck0d/b513bbFMIJr05bAvRxDLZDCG6VoEXz0lc9YlGqdVBcqUsGVqWKNT/Oo+7NSTDNWvNmmPbDWZBOJe1MlvkFEsYUN39SC+WsjzVARhW4FYMN0a78qeDs2XhKzC2sfZjv538AHHy0pV -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>tm2526946d1_ex1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0"><FONT STYLE="font-size: 10pt"><B>Exhibit 1.1</B></FONT></P>

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>IMMUNEERING CORPORATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>18,959,914 Shares
of Class&nbsp;A Common Stock (Par Value $0.001 per Share)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>UNDERWRITING
AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">September&nbsp;24, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Leerink Partners LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-size: 10pt">53
State Street</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">40th Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Boston, Massachusetts 02109</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Oppenheimer&nbsp;&amp; Co. Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">85 Broad Street, 23rd Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">New York, NY 10004</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Ladies and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Immuneering
Corporation, a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), proposes to issue and sell to Leerink Partners LLC and Oppenheimer&nbsp;&amp;
Co. Inc. (the &ldquo;<B>Underwriters</B>&rdquo;), 18,959,914 shares (the &ldquo;<B>Firm Shares</B>&rdquo;) of its Class&nbsp;A common
stock, $0.001 par value per share (the &ldquo;<B>Common Stock</B>&rdquo;). The Company also proposes to issue and sell to the Underwriters
not more than an additional 2,843,987 shares of Common Stock (the &ldquo;<B>Additional Shares</B>&rdquo;), if and to the extent that
the Underwriters shall have determined to exercise the right to purchase such additional shares granted to the Underwriters in Section&nbsp;2
hereof. The Firm Shares and the Additional Shares are hereinafter collectively referred to as the &ldquo;<B>Shares</B>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Concurrently
with the sale of the Shares, the Company will sell 2,708,559 shares of Common Stock (or in certain circumstances in lieu of shares of
Common Stock, shares of the Company&rsquo;s non-voting Class&nbsp;B common stock, $0.001 par value per share) in a private placement
to Aventis Inc. (&ldquo;<B>Sanofi</B>&rdquo;), at a price per share of $9.23 (the &ldquo;<B>Concurrent Sanofi Placement</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Company has filed with the Securities and Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;) a registration statement on Form&nbsp;S-3
(File No.&nbsp;333-289589), including a prospectus relating to certain securities of the Company, including the Shares, to be issued
from time to time by the Company. Such registration statement, as amended, at the time of effectiveness, including the information (if
any) deemed to be part of the registration statement pursuant to Rule&nbsp;430B under the Securities Act of 1933, as amended (the &ldquo;<B>Securities
Act</B>&rdquo;), is hereinafter referred to as the &ldquo;<B>Registration Statement</B>.&rdquo; The base prospectus filed as part of
the Registration Statement, in the form in which it has most recently been filed with the Commission on or prior to the date of this
underwriting agreement (this &ldquo;<B>Agreement</B>&rdquo;) is hereinafter referred to as the &ldquo;<B>Basic Prospectus</B>.&rdquo;
The preliminary prospectus supplement relating to the Shares filed with the Commission pursuant to Rule&nbsp;424(b)&nbsp;under the Securities
Act is hereinafter referred to as the &ldquo;<B>Preliminary Prospectus</B>.&rdquo; The Basic Prospectus, as amended and supplemented
by the Preliminary Prospectus specifically relating to the Shares in the form first used to confirm sales of the Shares (or in the form
first made available to the Underwriters by the Company to meet requests of purchasers pursuant to Rule&nbsp;173 under the Securities
Act) is hereinafter referred to as the &ldquo;<B>Pricing Prospectus</B>.&rdquo; The form of the final prospectus relating to the Shares
filed with the Commission pursuant to Rule&nbsp;424(b)&nbsp;under the Securities Act is hereinafter referred to as the &ldquo;<B>Prospectus</B>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">For
purposes of this Agreement, &ldquo;<B>free writing prospectus</B>&rdquo; has the meaning set forth in Rule&nbsp;405 under the Securities
Act, &ldquo;<B>Time of Sale Prospectus</B>&rdquo; means the Pricing Prospectus together with the free writing prospectuses, if any, each
identified in Schedule II hereto and the pricing information set forth in Schedule II hereto, and &ldquo;<B>broadly available road show</B>&rdquo;
means a &ldquo;bona fide electronic road show&rdquo; as defined in Rule&nbsp;433(h)(5)&nbsp;under the Securities Act that has been made
available without restriction to any person. As used herein, the terms &ldquo;Registration Statement,&rdquo; &ldquo;Basic Prospectus,&rdquo;
 &ldquo;Preliminary Prospectus,&rdquo; &ldquo;Time of Sale Prospectus&rdquo; and &ldquo;Prospectus&rdquo; shall include the documents,
if any, incorporated by reference therein as of the date hereof. The terms &ldquo;<B>supplement</B>,&rdquo; &ldquo;<B>amendment</B>&rdquo;
and &ldquo;<B>amend</B>&rdquo; as used herein with respect to (a)&nbsp;the Basic Prospectus, the Time of Sale Prospectus, any Preliminary
Prospectus or the Prospectus shall include any post-effective amendment to the Registration Statement, any prospectus supplement relating
to the Shares filed with the Commission pursuant to Rule&nbsp;424(b)&nbsp;under the Securities Act and all documents subsequently filed
by the Company with the Commission pursuant to the Securities Exchange Act of 1934, as amended (the &ldquo;<B>Exchange Act</B>&rdquo;),
that are deemed to be incorporated by reference therein, in each case after the date of the Basic Prospectus, such Preliminary Prospectus,
or the Prospectus, as the case may be and (b)&nbsp;the Registration Statement shall be deemed to refer to and include any annual report
of the Company filed pursuant to Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;of the Exchange Act after the effective date of the Registration
Statement that is incorporated by reference in the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Representations
and Warranties. </I>The Company represents and warrants to and agrees with each of the Underwriters that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Registration Statement has become effective; no stop order suspending the effectiveness of the Registration Statement is in effect, and
no proceedings for such purpose or pursuant to Section&nbsp;8A under the Securities Act are pending before or threatened by the Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;(i)&nbsp;Each
document, if any, filed or to be filed pursuant to the Exchange Act and incorporated by reference in the Time of Sale Prospectus or the
Prospectus complied or will comply when so filed in all material respects with the Exchange Act and the applicable rules&nbsp;and regulations
of the Commission thereunder, (ii)&nbsp;the Registration Statement, when it became effective, did not contain and, as amended or supplemented,
if applicable, as of the date of such amendment or supplement, will not contain any untrue statement of a material fact or omit to state
a material fact required to be stated therein or necessary to make the statements therein not misleading, (iii)&nbsp;the Registration
Statement and the Prospectus comply and, as amended or supplemented, if applicable, as of the date of such amendment or supplement, will
comply in all material respects with the Securities Act and the applicable rules&nbsp;and regulations of the Commission thereunder, (iv)&nbsp;the
Time of Sale Prospectus does not, and at the time of the sale of the Shares in connection with the offering when the Prospectus is not
yet available to prospective purchasers and at the Closing Date (as defined in Section&nbsp;4), the Time of Sale Prospectus, as then
amended or supplemented by the Company, if applicable, as of the date of such amendment or supplement, will not contain any untrue statement
of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under
which they were made, not misleading, (v)&nbsp;each broadly available road show, if any, when considered together with the Time of Sale
Prospectus, does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
therein, in the light of the circumstances under which they were made, not misleading and (vi)&nbsp;the Prospectus, as of its date, does
not contain and, as amended or supplemented, if applicable, as of the date of such amendment or supplement, will not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances
under which they were made, not misleading, except that the representations and warranties set forth in this paragraph do not apply to
statements or omissions in the Registration Statement, the Time of Sale Prospectus or the Prospectus based upon information relating
to any Underwriter furnished to the Company in writing by or on behalf of such Underwriter expressly for use therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;(i)&nbsp;At
the earliest time after the filing of the Registration Statement that the Company or another offering participant made a bona fide offer
(within the meaning of Rule&nbsp;164(h)(2)) of the Securities Act and (ii)&nbsp;as of the date hereof, the Company is not an &ldquo;ineligible
issuer&rdquo; in connection with the offering pursuant to Rules&nbsp;164, 405 and 433 under the Securities Act. Any free writing prospectus
that the Company is required to file pursuant to Rule&nbsp;433(d)&nbsp;under the Securities Act has been, or will be, filed with the
Commission in accordance with the requirements of the Securities Act and the applicable rules&nbsp;and regulations of the Commission
thereunder. Each free writing prospectus that the Company has filed, or is required to file, pursuant to Rule&nbsp;433(d)&nbsp;under
the Securities Act or that was prepared by or on behalf of or used or referred to by the Company complies or will comply, as of the date
of such filing, in all material respects with the applicable requirements of the Securities Act and the applicable rules&nbsp;and regulations
of the Commission thereunder. Except for the free writing prospectuses, if any, identified in Schedule II hereto, and electronic road
shows, if any, each furnished to the Underwriters before first use, the Company has not prepared, used or referred to, and will not,
without the Underwriters&rsquo; prior consent, prepare, use or refer to, any free writing prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Company has been duly incorporated, is validly existing as a corporation in good standing under the laws of the jurisdiction of its incorporation,
has the corporate power and authority to own or lease its property and to conduct its business as described in the Time of Sale Prospectus
and is duly qualified to transact business and is in good standing in each jurisdiction in which the conduct of its business or its ownership
or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good standing would
not, singly or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken
as a whole.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Each
subsidiary of the Company has been duly incorporated, organized or formed, is validly existing as a corporation or other business entity
in good standing under the laws of the jurisdiction of its incorporation, organization or formation (to the extent that such concepts
are applicable in such jurisdiction), has the corporate or other business entity power and authority to own or lease its property and
to conduct its business as described in the Time of Sale Prospectus and is duly qualified to transact business and is in good standing
in each jurisdiction (to the extent that such concepts are applicable in such jurisdiction) in which the conduct of its business or its
ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good
standing would not, singly or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its subsidiaries,
taken as a whole; all of the issued shares of capital stock or other equity interests of each subsidiary of the Company have been duly
and validly authorized and issued, are fully paid and non-assessable (to the extent that such concepts are applicable in such jurisdiction)
and are owned directly or indirectly by the Company, free and clear of all liens, encumbrances, equities or claims.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;This
Agreement has been duly authorized, executed and delivered by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
authorized capital stock of the Company (including the Shares) conform as to legal matters, in all material respects, to the description
thereof contained in each of the Time of Sale Prospectus and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
shares of Common Stock outstanding prior to the issuance of the Shares have been duly authorized and are validly issued, fully paid and
non-assessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Shares have been duly authorized and, when issued, delivered and paid for in accordance with the terms of this Agreement, will be validly
issued, fully paid and non-assessable, and the issuance of the Shares will not be subject to any preemptive or similar rights that have
not been validly waived.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
execution and delivery by the Company of, and the performance by the Company of its obligations under, this Agreement will not contravene
(i)&nbsp;any provision of applicable law, (ii)&nbsp;the certificate of incorporation or by-laws of the Company, (iii)&nbsp;any agreement
or other instrument binding upon the Company or any of its subsidiaries that is material to the Company and its subsidiaries, taken as
a whole, or (iv)&nbsp;any judgment, order or decree of any governmental body, agency or court having jurisdiction over the Company or
any subsidiary, except in the case of clauses (i), (iii)&nbsp;and (iv), where such contravention would not, individually or in the aggregate,
reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole, and no consent, approval,
authorization or order of, or qualification with, any governmental body or agency is required for the performance by the Company of its
obligations under this Agreement, except such as have been obtained or waived or as may be required by the securities or Blue Sky laws
of the various states or the rules&nbsp;and regulations of the Financial Industry Regulatory Authority (&ldquo;<B>FINRA</B>&rdquo;) in
connection with the offer and sale of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;There
has not occurred any material adverse change, or any development involving a prospective material adverse change, in the condition, financial
or otherwise, or in the earnings, business or operations of the Company and its subsidiaries, taken as a whole, from that set forth in
the Time of Sale Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;There
are no legal or governmental proceedings pending or, to the Company&rsquo;s knowledge, threatened to which the Company or any of its
subsidiaries is a party or to which any of the properties of the Company or any of its subsidiaries is subject (i)&nbsp;other than proceedings
accurately described in all material respects in the Time of Sale Prospectus and proceedings that would not, singly or in the aggregate,
reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole, or on the power or ability
of the Company to perform its obligations under this Agreement or to consummate the transactions contemplated by the Time of Sale Prospectus
(including the issuance and sale of the securities in the Concurrent Sanofi Placement) or (ii)&nbsp;that are required to be described
in the Registration Statement or the Prospectus and are not so described in all material respects; and there are no statutes, regulations,
contracts or other documents to which the Company is subject or by which the Company is bound that are required to be described in the
Registration Statement or the Prospectus or to be filed as exhibits to the Registration Statement that are not described in all material
respects or filed as required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(m)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Each
Preliminary Prospectus filed as part of the Registration Statement as originally filed or as part of any amendment thereto, or filed
pursuant to Rule&nbsp;424 under the Securities Act, complied when so filed in all material respects with the applicable requirements
of the Securities Act and the applicable rules&nbsp;and regulations of the Commission thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(n)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Company is not, and after giving effect to the offering and sale of the Shares and the issuance and sale of the securities in the Concurrent
Sanofi Placement, and the application of the proceeds thereof as described in the Prospectus will not be, required to register as an
 &ldquo;investment company&rdquo; as such term is defined in the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(o)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="background-color: white">The
Company and each of its subsidiaries (i)&nbsp;are in compliance with any and all applicable foreign, federal, state and local laws and
regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants
or contaminants (&ldquo;<B>Environmental Laws</B>&rdquo;), (ii)&nbsp;have received all permits, licenses or other approvals required
of them under applicable Environmental Laws to conduct their respective businesses and (iii)&nbsp;are in compliance with all terms and
conditions of any such permit, license or approval, except where such noncompliance with Environmental Laws, failure to receive required
permits, licenses or other approvals or failure to comply with the terms and conditions of such permits, licenses or approvals would
not, singly or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken
as a whole.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(p)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="background-color: white">There
are no costs or liabilities associated with Environmental Laws (including, without limitation, any capital or operating expenditures
required for clean-up, closure of properties or compliance with Environmental Laws or any permit, license or approval, any related constraints
on operating activities and any potential liabilities to third parties) which would, singly or in the aggregate, have a material adverse
effect on the Company and its subsidiaries, taken as a whole.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(q)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;There
are no contracts, agreements or understandings between the Company and any person granting such person the right to require the Company
to file a registration statement under the Securities Act with respect to any securities of the Company or to require the Company to
include such securities with the Shares registered pursuant to the Registration Statement, except as otherwise have been validly waived
in connection with the issuance and sale of the Shares contemplated hereby and as described in the Time of Sale Prospectus and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(r)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;(i)&nbsp;None
of the Company or any of its subsidiaries or affiliates, or any director or officer thereof, nor, to the Company&rsquo;s knowledge, any
employee, agent or representative of the Company or of any of its subsidiaries or affiliates, has taken or will take any action in furtherance
of an offer, payment, promise to pay, or authorization or approval of the payment, giving or receipt of money, property, gifts or anything
else of value, directly or indirectly, to any government official (including any officer or employee of a government or government-owned
or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any
of the foregoing, or any political party or party official or candidate for political office) (&ldquo;<B>Government Official</B>&rdquo;)
in order to influence official action, or to any person in violation of any applicable anti-corruption laws; (ii)&nbsp;the Company and
each of its subsidiaries and affiliates have conducted their businesses in compliance with applicable anti-corruption laws and have instituted
and maintained and will continue to maintain policies and procedures reasonably designed to promote and achieve compliance with such
laws and with the representations and warranties contained herein; and (iii)&nbsp;neither the Company nor any of its subsidiaries will
use, directly or indirectly, the proceeds of the offering or the proceeds from the Sanofi Concurrent Placement in furtherance of an offer,
payment, promise to pay, or authorization of the payment or giving of money, or anything else of value, to any person in violation of
any applicable anti-corruption laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(s)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
operations of the Company and each of its subsidiaries are and have been conducted at all times in material compliance with all applicable
financial recordkeeping and reporting requirements, including those of the Bank Secrecy Act, as amended by Title III of the Uniting and
Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (USA PATRIOT Act), and
the applicable anti-money laundering statutes of jurisdictions where the Company and each of its subsidiaries conduct business, the rules&nbsp;and
regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental
agency (collectively, the &ldquo;<B>Anti-Money Laundering Laws</B>&rdquo;), and no action, suit or proceeding by or before any court
or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Anti-Money
Laundering Laws is pending or, to the knowledge of the Company, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(t)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;(i)&nbsp;None
of the Company, any of its subsidiaries, or any director or officer of the Company nor, to the Company&rsquo;s knowledge, any employee,
agent, affiliate or representative of the Company or any of its subsidiaries, is an individual or entity (&ldquo;<B>Person</B>&rdquo;)
that is, or is owned or controlled by one or more Persons that are:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(A)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
subject of any sanctions administered or enforced by the U.S. Department of the Treasury&rsquo;s Office of Foreign Assets Control, the
United Nations Security Council, the European Union, His Majesty&rsquo;s Treasury or other relevant sanctions authority (collectively,
 &ldquo;<B>Sanctions</B>&rdquo;), or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(B)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;located,
organized or resident in a country or territory that is the subject of Sanctions (including, without limitation, the so-called Donetsk
People&rsquo;s Republic and Luhansk People&rsquo;s Republic regions of Ukraine or non-Ukrainian government controlled areas of Kherson
and Zaporizhzh, Crimea, Cuba,&nbsp;Iran, North Korea and Syria).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Company will not, directly or indirectly, use the proceeds of the offering, or lend, contribute or otherwise make available such proceeds
to any subsidiary, joint venture partner or other Person:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(A)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to
fund or facilitate any activities or business of or with any Person or in any country or territory that, at the time of such funding
or facilitation, is the subject of Sanctions; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(B)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;in
any other manner that will result in a violation of Sanctions by any Person (including any Person participating in the offering, whether
as underwriter, advisor, investor or otherwise).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Company and its subsidiaries have not knowingly engaged in, are not now knowingly engaged in, and will not engage in, any dealings or
transactions with any Person, or in any country or territory, that at the time of the dealing or transaction is or was the subject of
Sanctions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(u)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Subsequent
to the respective dates as of which information is given in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus,
(i)&nbsp;the Company and its subsidiaries, taken as a whole, have not incurred any material liability or obligation, direct or contingent,
nor entered into any material transaction; (ii)&nbsp;the Company has not purchased any of its outstanding capital stock (other than from
its employees or other service providers in connection with the termination of their service pursuant to the terms of the equity compensation
plans or agreements described in the Time of Sale Prospectus), nor declared, paid or otherwise made any dividend or distribution of any
kind on its capital stock other than ordinary and customary dividends; and (iii)&nbsp;there has not been any material change in the capital
stock, short-term debt or long-term debt of the Company and its subsidiaries, taken as a whole, except in each case as described in each
of the Registration Statement, the Time of Sale Prospectus and the Prospectus, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Company and its subsidiaries do not own any real property. The Company and its subsidiaries have good and marketable title to all personal
property (other than intellectual property which is addressed exclusively in Section&nbsp;1(w)&nbsp;below) owned by them which is material
to the business of the Company and its subsidiaries, in each case free and clear of all liens, encumbrances and defects except such as
do not materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such
property by the Company and its subsidiaries; and any real property and buildings held under lease by the Company and its subsidiaries
are held by them under valid, subsisting and enforceable leases with such exceptions as are not material and would not reasonably be
expected to materially interfere with the use made and proposed to be made of such property and buildings by the Company and its subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(w)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="background-color: white">Except
as described in the Registration Statement, the Time of Sale Prospectus or the Prospectus, (i)&nbsp;the Company and its subsidiaries
own or have a valid license to or can acquire on reasonable terms all patents, copyrights, know how (including trade secrets and other
unpatented and/or unpatentable proprietary or confidential information, systems or procedures), trademarks, service marks and trade names
(collectively, &ldquo;<B>Intellectual Property Rights</B>&rdquo;) used in or reasonably necessary to the conduct of their businesses
as currently operated, except where the failure to own, possess, license, have the right to use or the ability to acquire any of the
foregoing would not reasonably be expected to result, singly or in the aggregate, in a material adverse effect on the Company and its
subsidiaries, taken as a whole; (ii)&nbsp;the Intellectual Property Rights owned by the Company and its subsidiaries and, to the Company&rsquo;s
knowledge, the Intellectual Property Rights exclusively licensed to the Company and its subsidiaries, in each case, which are material
to the conduct of the business of the Company and its subsidiaries as currently conducted, are valid, subsisting and enforceable, and
there is no pending or, to the Company&rsquo;s knowledge, threatened action, suit, proceeding or claim by others in writing challenging
the validity, scope or enforceability of any such Intellectual Property Rights except as any such pending or threatened action, suit,
proceeding or claim would not reasonably be expected, singly or in the aggregate, to have a material adverse effect on the Company and
its subsidiaries, taken as a whole; (iii)&nbsp;neither the Company nor any of its subsidiaries has received any written notice alleging
any infringement, misappropriation or other violation of Intellectual Property Rights which, singly or in the aggregate, if the subject
of an unfavorable decision, ruling or finding, would have a material adverse effect on the Company and its subsidiaries, taken as a whole;
(iv)&nbsp;except as would not reasonably be expected, singly or in the aggregate, to have a material adverse effect on the Company and
its subsidiaries, taken as a whole, to the Company&rsquo;s knowledge, no third party is infringing, misappropriating or otherwise violating,
or has infringed, misappropriated or otherwise violated, any Intellectual Property Rights owned by the Company; (v)&nbsp;to the Company&rsquo;s
knowledge, neither the Company nor any of its subsidiaries infringes, misappropriates or otherwise violates, or has infringed, misappropriated
or otherwise violated, any Intellectual Property Rights of a third party in any respect that would reasonably be expected, singly or
in the aggregate, to have a material adverse effect on the Company and its subsidiaries, taken as a whole; (vi)&nbsp;to the Company&rsquo;s
knowledge, all employees or contractors engaged on behalf of the Company or any subsidiary of the Company in the development of Intellectual
Property Rights which are material to the business of the Company or any subsidiary have executed an invention assignment agreement whereby
such employees or contractors presently assign all of their right, title and interest in and to such Intellectual Property Rights to
the Company or the applicable subsidiary, and, to the Company&rsquo;s knowledge, no such agreement has been breached or violated; and
(vii)&nbsp;the Company and its subsidiaries use, and have used, commercially reasonable efforts in accordance with customary industry
practice to appropriately maintain all information intended to be maintained as a trade secret.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(x)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;(i)&nbsp;The
Company and its subsidiaries use and have used any and all software and other materials distributed under a &ldquo;free,&rdquo; &ldquo;open
source,&rdquo; or similar licensing model (&ldquo;<B>Open Source Software</B>&rdquo;) in compliance with all license terms applicable
to such Open Source Software, except as any such noncompliance would not reasonably be expected, singly or in the aggregate, to have
a material adverse effect on the Company and its subsidiaries, taken as a whole; and (ii)&nbsp;neither the Company nor any of its subsidiaries
uses or distributes or has used or distributed any Open Source Software in any manner that requires or has required (A)&nbsp;the Company
or any of its subsidiaries to permit reverse engineering of any software code or other technology owned by the Company or any of its
subsidiaries or (B)&nbsp;any software code or other technology owned by the Company or any of its subsidiaries to be (1)&nbsp;disclosed
or distributed in source code form, (2)&nbsp;licensed for the purpose of making derivative works or (3)&nbsp;redistributed at no charge,
except, in each case of (A)&nbsp;and (B), as would not reasonably be expected, singly or in the aggregate, to have a material adverse
effect on the Company and its subsidiaries, taken as a whole.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(y)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;(i)&nbsp;The
Company and each of its subsidiaries have complied in all material respects and are presently in compliance in all material respects
with all internal privacy policies, contractual obligations, applicable laws or statutes, and judgments, orders, rules&nbsp;and regulations
of any court or arbitrator or other governmental or regulatory authority, in each case, relating to the collection, use, transfer, import,
export, storage, protection, disposal and disclosure by the Company or any of its subsidiaries of personally identifiable or regulated
data (&ldquo;<B>Data Security Obligations</B>&rdquo;, and such data, &ldquo;<B>Data</B>&rdquo;); (ii)&nbsp;the Company has not received
any written notification of or complaint regarding material non-compliance with any Data Security Obligation; and (iii)&nbsp;there is
no action, suit or proceeding by or before any court or governmental agency, authority or body pending or, to the Company&rsquo;s knowledge,
threatened alleging non-compliance with any Data Security Obligation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(z)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Company and each of its subsidiaries have implemented commercially reasonable controls, policies, procedures and technological safeguards
to maintain and protect the material information technology systems and Data used in connection with the operation of the Company&rsquo;s
and its subsidiaries&rsquo; businesses. Without limiting the foregoing, the Company and its subsidiaries have used commercially reasonable
efforts to implement appropriate controls, policies, procedures and technological safeguards to establish and maintain reasonable data
protection controls, policies and procedures that are designed to protect against and prevent breach, destruction, loss, unauthorized
distribution, use, access, disablement, misappropriation or modification, or other compromise or misuse of Data used in connection with
the operation of the Company&rsquo;s and its subsidiaries&rsquo; businesses (&ldquo;<B>Breach</B>&rdquo;). There has been no material
Breach, and the Company and its subsidiaries have not been notified of and have no knowledge of any event or condition that would reasonably
be expected to result in, any such material Breach.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(aa)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No
material labor dispute with the employees of the Company or any of its subsidiaries exists, or, to the knowledge of the Company, is imminent;
and the Company is not aware of any existing, threatened or imminent labor disturbance by the employees of any of its principal suppliers,
manufacturers or contractors that would have a material adverse effect on the Company and its subsidiaries, taken as a whole.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(bb)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Company and each of its subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and
in such amounts as in the Company&rsquo;s reasonable judgment are prudent and customary in the businesses in which they are engaged;
neither the Company nor any of its subsidiaries has been refused any insurance coverage sought or applied for; and neither the Company
nor any of its subsidiaries has any reason to believe that it will not be able to renew its existing insurance coverage as and when such
coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that would
not, singly or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken
as a whole, except as described in the Time of Sale Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(cc)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Company possesses, and is in compliance with the terms of, all certificates, approvals, clearances, registrations, exemptions, franchises,
licenses, permits and other authorizations necessary to the conduct of the business as currently conducted by it as disclosed in the
Time of Sale Prospectus (collectively, &ldquo;<B>Licenses</B>&rdquo;), including without limitation, all such Licenses required by the
United States Food and Drug Administration (the &ldquo;<B>FDA</B>&rdquo;), except where the failure to so possess or be in compliance
would not reasonably be expected to have a material adverse effect. All such Licenses are in full force and effect and the Company is
not in violation of any term of such License, except as would not, individually or in the aggregate, reasonably be expected to have a
material adverse effect. The Company has not received any written notice of proceedings or other actions relating to the suspension,
revocation or modification of any such Licenses that, if taken or determined adversely to the Company, would, individually or in the
aggregate, reasonably be expected to have a material adverse effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(dd)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Company is, and during the last three (3)&nbsp;years, has been, in compliance with all Health Care Laws, except where failure to comply
would not be expected, individually or in the aggregate, to result in a material adverse effect. For purposes of this Agreement, &ldquo;<B>Health
Care Laws</B>&rdquo; means: (i)&nbsp;the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Section&nbsp;301 et seq.); (ii)&nbsp;all applicable
federal, state, local and foreign health care fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute
(42 U.S.C. Section&nbsp;1320a-7b(b)), the federal Civil False Claims Act (31 U.S.C. Section&nbsp;3729 et seq.), the criminal false statements
law (42 U.S.C. Section&nbsp;1320a-7b(a)), 18 U.S.C. Sections 286 and 287, the health care fraud criminal provisions under the Health
Insurance Portability and Accountability Act (42 U.S.C. Section&nbsp;1320d et seq.) (&ldquo;<B>HIPAA</B>&rdquo;), the civil monetary
penalties law (42 U.S.C. Section&nbsp;1320a-7a), the exclusion law (42 U.S.C. Section&nbsp;1320a-7), the federal Physician Payments Sunshine
Act (42 U.S.C. Section&nbsp;1320-7h), and applicable laws governing government funded or sponsored healthcare programs; (iii)&nbsp;HIPAA,
as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. Section&nbsp;17921 et seq.); (iv)&nbsp;all
other similar local, state, federal, national, supranational and foreign laws; and (v)&nbsp;the regulations promulgated pursuant to such
laws set forth in subparts (i)&nbsp;through (iv). Except as would not be expected, individually or in the aggregate, to result in a material
adverse effect, during the last three (3)&nbsp;years, the Company has not received written notice of any claim, subpoena, civil investigative
demand, action, suit, unsealed complaint (including an unsealed <I>qui tam </I>complaint), proceeding, hearing, enforcement, investigation,
inquiry, arbitration or other action from any court or arbitrator or governmental authority or third party alleging that any product,
operation, or activity is in violation of any Health Care Laws nor, to the Company&rsquo;s knowledge, is any such claim, subpoena, civil
investigative demand, action, suit, unsealed complaint (including an unsealed <I>qui tam </I>complaint), proceeding, hearing, enforcement,
investigation, inquiry, arbitration or other action threatened. Except as would not be expected, individually or in the aggregate, to
result in a material adverse effect, during the last three (3)&nbsp;years, the Company has filed, maintained or submitted all reports,
documents, forms, notices, applications, records, claims, submissions and supplements or amendments (&ldquo;<B>Submissions</B>&rdquo;)
as required by any Health Care Laws, and all such Submissions were accurate on the date filed (or were corrected or supplemented by a
subsequent submission). The Company is not, and has not been, a party to any corporate integrity agreements, monitoring agreements, consent
decrees, settlement orders, or similar agreements with or imposed by any governmental authority. During the last three (3)&nbsp;years,
neither the Company nor any of its respective employees, officers, directors, or, to the Company&rsquo;s knowledge, agents has been excluded,
suspended or debarred from participation in any U.S. federal health care program or human clinical research or, to the knowledge of the
Company, is subject to an inquiry, investigation, proceeding or other similar action by the FDA, or other applicable regulatory authority
or other governmental entity that could reasonably be expected to result in debarment, suspension or exclusion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ee)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
preclinical tests and clinical trials, to the extent applicable, conducted by or on behalf of, or sponsored by, the Company and that
are described in, or the results of which are referred to in, the Time of Sale Prospectus were and, if still pending, are being conducted
in all material respects in accordance with all applicable laws, rules, and regulations, including applicable Health Care Laws; each
description of such tests and trials, and the results thereof, contained in the Time of Sale Prospectus is accurate in all material respects,
and the Company has no knowledge of any other studies or tests the results of which are materially inconsistent with, or otherwise reasonably
call into question, the results described or referred to in the Time of Sale Prospectus; the Company has not received any written notices
or other written correspondence from any governmental authority requiring the termination, suspension or material modification of any
preclinical tests or clinical trials that are described or referred to in the Time of Sale Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ff)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
financial statements included or incorporated by reference in each of the Registration Statement, the Time of Sale Prospectus and the
Prospectus, together with the related schedules and notes thereto, comply as to form in all material respects with the applicable accounting
requirements of the Securities Act and present fairly in all material respects the consolidated financial position of the Company and
its subsidiaries as of the dates shown and its results of operations and cash flows for the periods shown, and such financial statements
have been prepared in conformity with generally accepted accounting principles in the United States (&ldquo;<B>U.S. GAAP</B>&rdquo;)
applied on a consistent basis throughout the periods covered thereby except for any normal year-end adjustments in the Company&rsquo;s
quarterly financial statements. The other financial information included in the Time of Sale Prospectus and the Prospectus has been derived
from the accounting or other records of the Company and its consolidated subsidiaries and presents fairly in all material respects the
information shown thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(gg)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
statistical and market-related data included in the Registration Statement, the Time of Sale Prospectus and the Prospectus are based
on or derived from sources that the Company believes, after reasonable inquiry, to be reliable and accurate in all material respects
and, to the extent required, the Company has obtained the written consent to the use of such data from such sources.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(hh)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;RSM
US LLP, who have certified certain financial statements of the Company and its subsidiaries and delivered its report with respect to
the audited consolidated financial statements and schedules filed with the Commission as part of the Registration Statement and included
in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus, is an independent registered public accounting
firm with respect to the Company within the applicable rules&nbsp;and regulations of the Commission and as required by the Securities
Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Company and its subsidiaries, taken as a whole, maintain a system of internal accounting controls sufficient to provide reasonable assurance
that (i)&nbsp;transactions are executed in accordance with management&rsquo;s general or specific authorizations; (ii)&nbsp;transactions
are recorded as necessary to permit preparation of financial statements in conformity with U.S. GAAP and to maintain asset accountability;
(iii)&nbsp;access to assets is permitted only in accordance with management&rsquo;s general or specific authorization; (iv)&nbsp;the
recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with
respect to any differences; and (v)&nbsp;the interactive data in eXtensible Business Reporting Language included or incorporated by reference
in the Registration Statement is accurate in all material respects. Since the end of the Company&rsquo;s most recent audited fiscal year,
there has been (i)&nbsp;no material weakness in the Company&rsquo;s internal control over financial reporting (whether or not remediated)
and (ii)&nbsp;no change in the Company&rsquo;s internal control over financial reporting that has materially and adversely affected,
or is reasonably likely to materially and adversely affect, the Company&rsquo;s internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(jj)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement fairly
presents the information called for in all material respects and has been prepared in accordance with the Commission&rsquo;s rules&nbsp;and
guidelines applicable thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(kk)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;There
is and has been no failure on the part of the Company or any of the Company&rsquo;s directors or officers, in their capacities as such,
to comply in all material respects with any provision of the Sarbanes-Oxley Act of 2002 and the rules&nbsp;and regulations promulgated
in connection therewith, including Section&nbsp;402 related to loans and Sections 302 and 906 related to certifications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ll)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Company and each of its subsidiaries have filed all federal, state, local and foreign tax returns required to be filed or have requested
extensions thereof and have paid all taxes required to be paid by them (except for cases in which the failure to file or pay would not,
singly or in the aggregate, have a material adverse effect on the Company and its subsidiaries, taken as a whole, or except as currently
being contested in good faith and for which reserves required by U.S. GAAP have been created in the financial statements of the Company),
and no tax deficiency has been determined adversely to the Company or any of its subsidiaries which, singly or in the aggregate, has
had (nor does the Company have any notice or knowledge of any tax deficiency which could reasonably be expected to be determined adversely
to the Company or its subsidiaries and which could reasonably be expected to have) a material adverse effect on the Company and its subsidiaries,
taken as a whole.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(mm)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;From
the time of initial filing of the Registration Statement with the Commission through the date hereof, the Company has been and is an
 &ldquo;emerging growth company,&rdquo; as defined in Section&nbsp;2(a)&nbsp;of the Securities Act (an &ldquo;<B>Emerging Growth Company</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(nn)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Company (i)&nbsp;has not alone engaged in any Testing-the-Waters Communication with any person other than Testing-the-Waters Communications
with the consent of the Underwriters with entities that are reasonably believed to be qualified institutional buyers within the meaning
of Rule&nbsp;144A under the Securities Act or institutions that are reasonably believed to be accredited investors within the meaning
of Rule&nbsp;501 under the Securities Act and (ii)&nbsp;other than with the express written consent of the Underwriters, has not authorized
anyone other than the Underwriters to engage in Testing-the-Waters Communications. The Company reconfirms that the Underwriters have
been authorized to act on its behalf in undertaking Testing-the-Waters Communications. The Company has not distributed any Written Testing-the-Waters
Communication other than those listed on Schedule III hereto. &ldquo;<B>Written Testing-the-Waters Communication</B>&rdquo; means any
Testing-the-Waters Communication that is a written communication within the meaning of Rule&nbsp;405 under the Securities Act. &ldquo;<B>Testing-the-Waters
Communication</B>&rdquo; means any oral or written communication with potential investors undertaken in reliance on Section&nbsp;5(d)&nbsp;or
Rule&nbsp;163B under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(oo)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Neither
the Company nor any of its subsidiaries has any securities rated by any &ldquo;nationally recognized statistical rating organization,&rdquo;
as such term is defined in Section&nbsp;3(a)(62) of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(pp)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;As
of the time of the sale of the Shares in connection with the offering when the Prospectus is not yet available to prospective purchasers,
none of (A)&nbsp;the Time of Sale Prospectus, (B)&nbsp;any free writing prospectus, when considered together with the Time of Sale Prospectus,
and (C)&nbsp;any individual Written Testing-the-Waters Communication, when considered together with the Time of Sale Prospectus, included,
includes or will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in
order to make the statements therein, in the light of the circumstances under which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(qq)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Company maintains disclosure controls and procedures (as such is defined in Rule&nbsp;13a-15(e)&nbsp;under the Exchange Act) that comply
with the requirements of the Exchange Act; such disclosure controls and procedures have been designed to ensure that information required
to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported
within the time periods specified in the Commission&rsquo;s rules&nbsp;and forms, including controls and procedures designed to ensure
that such information is accumulated and communicated to the Company&rsquo;s management to allow timely decisions regarding disclosures.
The Company has conducted evaluations of the effectiveness of their disclosure controls as required by Rule&nbsp;13a-15 of the Exchange
Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(rr)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Company is subject to and in compliance in all material respects with the reporting requirements of Section&nbsp;13 or Section&nbsp;15(d)&nbsp;of
the Exchange Act. Except as disclosed in the Registration Statement, the Common Stock is registered pursuant to Section&nbsp;12(b)&nbsp;or
Section&nbsp;12(g)&nbsp;of the Exchange Act and is listed on Nasdaq, and the Company has taken no action designed to, or reasonably likely
to have the effect of, terminating the registration of the Common Stock under the Exchange Act or delisting the Common Stock from Nasdaq,
nor has the Company received any notification that the Commission or Nasdaq is contemplating terminating such registration or listing.
Except as disclosed in the Registration Statement, the Company has submitted a Listing of Additional Shares Notification Form&nbsp;with
Nasdaq covering the Shares; the Company has taken all reasonably necessary actions to ensure that it will be in compliance with all applicable
corporate governance requirements set forth in Nasdaq&rsquo;s listing rules&nbsp;that are then in effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ss)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Company has not relied upon the Underwriters or legal counsel for the Underwriters for any legal, tax or accounting advice in connection
with the offering and sale of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(tt)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Neither
the Company nor any of its subsidiaries is a &ldquo;covered foreign person&rdquo;, as that term is defined in 31 C.F.R. &sect; 850.209.
Neither the Company nor any of its subsidiaries currently engages, or has plans to engage, directly or indirectly, in a &ldquo;covered
activity&rdquo;, as that term is defined in 31 C.F.R. &sect; 850.208 (&ldquo;<B>Covered Activity</B>&rdquo;). The Company does not have
any joint venture that engages in or plans to engage in any Covered Activity. The Company also does not, directly or indirectly, hold
a board seat on, have a voting or equity interest in, or have any contractual power to direct or cause the direction of the management
or policies of any person or persons that engages or plans to engage in any Covered Activity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(uu)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
private placement purchase agreement relating to the Concurrent Sanofi Placement (the &ldquo;<B>Private Placement Purchase Agreement</B>&rdquo;),
has been duly authorized and executed and delivered by the Company and will constitute a valid and binding agreement of the Company,
enforceable against the Company in accordance with its terms, except as the enforcement thereof may be limited by bankruptcy, insolvency,
reorganization, moratorium or other similar laws relating to or affecting the rights and remedies of creditors or by general equitable
principles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(vv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
securities to be sold in the Concurrent Sanofi Placement have been duly authorized for issuance and sale, and when issued and delivered
by the Company pursuant to the Private Placement Purchase Agreement, will be validly issued and fully paid and non-assessable, and free
and clear of any pledge, lien, encumbrance, security interest or other claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ww)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;It
is not necessary, in connection with the offer or sale of securities to Sanofi pursuant to the Private Placement Purchase Agreement,
in the manner contemplated by the Private Placement Purchase Agreement, to register such offer or sale of securities under the Securities
Act, and such offer and sale will not be integrated with the offer and sale of the Shares as contemplated by this Agreement, the Registration
Statement, the Time of Sale Prospectus and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Agreements
to Sell and Purchase. </I>The Company hereby agrees to sell to the several Underwriters, and each Underwriter, upon the basis of the
representations and warranties herein contained, but subject to the terms and conditions hereinafter stated, agrees, severally and not
jointly, to purchase from the Company the respective number of Firm Shares set forth in Schedule I hereto opposite its name at $8.6762
per share (the &ldquo;<B>Purchase Price</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">On
the basis of the representations and warranties contained in this Agreement, and subject to its terms and conditions, the Company agrees
to sell to the Underwriters the Additional Shares, and the Underwriters shall have the right to purchase, severally and not jointly,
up to 2,843,987 Additional Shares at the Purchase Price, provided, however, that the amount paid by the Underwriters for any Additional
Shares shall be reduced by an amount per share equal to any dividends declared by the Company and payable on the Firm Shares but not
payable on such Additional Shares. The Underwriters may exercise this right in whole or from time to time in part by giving written notice
not later than 30 days after the date of this Agreement. Any exercise notice shall specify the number of Additional Shares to be purchased
by the Underwriters and the date on which such shares are to be purchased. Each purchase date must be at least one business day after
the written notice is given and may not be earlier than the closing date for the Firm Shares nor later than ten business days after the
date of such notice. On each day, if any, that Additional Shares are to be purchased (an &ldquo;<B>Option Closing Date</B>&rdquo;), each
Underwriter agrees, severally and not jointly, to purchase the number of Additional Shares (subject to such adjustments to eliminate
fractional shares as the Underwriters may determine) that bears the same proportion to the total number of Additional Shares to be purchased
on such Option Closing Date as the number of Firm Shares set forth in Schedule I hereto opposite the name of such Underwriter bears to
the total number of Firm Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Terms
of Public Offering. </I>The Company is advised by the Underwriters that the Underwriters propose to make a public offering of the Shares
as soon after this Agreement has become effective as in the Underwriters&rsquo; judgment is advisable. The Company is further advised
by you that the Shares are to be offered to the public initially at $9.23 per share (the &ldquo;Public Offering Price&rdquo;) and to
certain dealers selected by the Underwriters at a price that represents a concession not in excess of $0.33228 a share under the Public
Offering Price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Payment
and Delivery.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Payment
for the Firm Shares shall be made to the Company in Federal or other funds immediately available in New York City against delivery of
such Firm Shares for the respective accounts of the Underwriters at 10:00 a.m., New York City time, on September&nbsp;26, 2025, or at
such other time on the same date as shall be designated in writing by the Underwriters. The time and date of such payment are herein
after referred to as the &ldquo;<B>Closing Date</B>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Payment
for any Additional Shares shall be made to the Company in Federal or other funds immediately available in New York City against delivery
of such Additional Shares for the respective accounts of the several Underwriters at 10:00 a.m., New York City time, on the date specified
in the corresponding notice described in Section&nbsp;2 or at such other time on the same or on such other date, in any event not later
than October&nbsp;24, 2025, as shall be designated in writing by the Underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Firm Shares and Additional Shares shall be registered in such names and in such denominations as the Underwriters shall request in writing
not later than one full business day prior to the Closing Date or the applicable Option Closing Date, as the case may be. The Firm Shares
and Additional Shares shall be delivered to the Underwriters on the Closing Date or an Option Closing Date, as the case may be, with
any transfer taxes payable in connection with the transfer of the Shares to the Underwriters duly paid, against payment of the Purchase
Price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Conditions
to the Underwriters&rsquo; Obligations. </I>The obligations of the Company to sell the Shares to the Underwriters and the several obligations
of the Underwriters to purchase and pay for the Shares on the Closing Date are subject to the following conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Subsequent
to the execution and delivery of this Agreement and prior to the Closing Date:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;no
order suspending the effectiveness of the Registration Statement shall be in effect, and no proceeding for such purpose or pursuant to
Section&nbsp;8A under the Securities Act shall be pending before or threatened by the Commission; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;there
shall not have occurred any change, or any development involving a prospective change, in the condition, financial or otherwise, or in
the earnings, business or operations of the Company and its subsidiaries, taken as a whole, from that set forth in the Time of Sale Prospectus
that, in the Underwriters&rsquo; judgment, is material and adverse and that makes it, in the Underwriters&rsquo; judgment, impracticable
to market the Shares on the terms and in the manner contemplated in the Time of Sale Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Underwriters shall have received on the Closing Date a certificate, dated the Closing Date and signed by an executive officer of the
Company, to the effect set forth in Sections&nbsp;5(a)(i)&nbsp;and 5(a)(ii)&nbsp;above and to the effect that the representations and
warranties of the Company contained in this Agreement are true and correct as of the Closing Date and that the Company has complied with
all of the agreements and satisfied all of the conditions on its part to be performed or satisfied hereunder on or before the Closing
Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
officer signing and delivering such certificate may rely upon the best of his or her knowledge as to proceedings threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Underwriters shall have received on the Closing Date (i)&nbsp;an opinion and (ii)&nbsp;a negative assurance letter of Latham&nbsp;&amp;
Watkins LLP, outside counsel for the Company, dated the Closing Date, in form and substance reasonably satisfactory to the Underwriter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Underwriters shall have received on the Closing Date an opinion of Knobbe, Martens, Olson&nbsp;&amp; Bear, LLP, outside intellectual
property counsel for the Company, dated the Closing Date, in form and substance reasonably satisfactory to the Underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Underwriters shall have received on the Closing Date an opinion and negative assurance letter of Sidley Austin LLP, counsel for the Underwriters,
dated the Closing Date, in form and substance reasonably satisfactory to the Underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">With
respect to the negative assurance letters to be delivered pursuant to Sections 5(c)&nbsp;and 5(e)&nbsp;above, Latham&nbsp;&amp; Watkins
LLP and Sidley Austin LLP may state that their opinions and beliefs are based upon their participation in the preparation of the Registration
Statement, the Basic Prospectus, the Time of Sale Prospectus and the Prospectus and any amendments or supplements thereto and review
and discussion of the contents thereof, but are without independent check or verification, except as specified therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
opinion and negative assurance letter of Latham&nbsp;&amp; Watkins LLP described in Section&nbsp;5(c)&nbsp;above shall be rendered to
the Underwriters at the request of the Company and shall so state therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Underwriters shall have received, on each of the date hereof and the Closing Date, a letter dated the date hereof or the Closing Date,
as the case may be, in form and substance satisfactory to the Underwriters, from RSM US LLP, independent public accountants, containing
statements and information of the type ordinarily included in accountants&rsquo; &ldquo;comfort letters&rdquo; to underwriters with respect
to the financial statements and certain financial information contained in the Registration Statement, the Time of Sale Prospectus and
the Prospectus; <I>provided</I> that the letter delivered on the Closing Date shall use a &ldquo;cut-off date&rdquo; not earlier than
the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
 &ldquo;lock-up&rdquo; agreements, each substantially in the form of Exhibit&nbsp;A hereto, between the Underwriters and certain officers
and directors of the Company relating to sales and certain other dispositions of shares of Common Stock or certain other securities,
delivered to the Underwriters on or before the date hereof, shall be in full force and effect on the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-size: 10pt; background-color: white">(i)&#8239;The
several obligations of the Underwriters to purchase Additional Shares hereunder are subject to the delivery to the Underwriters on the
applicable Option Closing Date of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-size: 10pt; background-color: white">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;a
certificate, dated the Option Closing Date and signed by an executive officer of the Company, confirming that the certificate delivered
on the Closing Date pursuant to Section&nbsp;5(b)&nbsp;hereof remains true and correct as of such Option Closing Date;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-size: 10pt; background-color: white">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;an
opinion and negative assurance letter of Latham&nbsp;&amp; Watkins LLP, outside counsel for the Company, dated the Option Closing Date,
relating to the Additional Shares to be purchased on such Option Closing Date and otherwise to the same effect as the opinion required
by Section&nbsp;&lrm;5(c)&nbsp;hereof;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-size: 10pt; background-color: white">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;an
opinion of Knobbe, Martens, Olson&nbsp;&amp; Bear, LLP, outside intellectual property counsel for the Company, dated the Option Closing
Date, relating to the Additional Shares to be purchased on such Option Closing Date and otherwise to the same effect as the respective
opinions required by Section&nbsp;&lrm;5(d)&nbsp;hereof;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-size: 10pt; background-color: white">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;an
opinion and negative assurance letter of Sidley Austin LLP, counsel for the Underwriters, dated the Option Closing Date, relating to
the Additional Shares to be purchased on such Option Closing Date and otherwise to the same effect as the opinion required by Section&nbsp;5(e)&nbsp;hereof;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-size: 10pt; background-color: white">(vi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;a
letter dated the Option Closing Date, in form and substance satisfactory to the Underwriters, from RSM US LLP, independent public accountants,
substantially in the same form and substance as the letter furnished to the Underwriters pursuant to Section&nbsp;5(f)&nbsp;hereof; <I>provided</I>
that the letter delivered on the Option Closing Date shall use a &ldquo;cut-off date&rdquo; not earlier than two business days prior
to such Option Closing Date; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-size: 10pt; background-color: white">(vii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;such
other documents as the Underwriters may reasonably request with respect to the good standing of the Company, the due authorization and
issuance of the Additional Shares to be sold on such Option Closing Date and other matters related to the issuance of such Additional
Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Covenants
of the Company. The Company covenants with each Underwriter as follows:</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To
furnish to the Underwriters, upon written request, without charge, two signed copies of the Registration Statement (including exhibits
thereto), prior to 10:00&nbsp;a.m.&nbsp;New York City time on the business day next succeeding the date of this Agreement and during
the period mentioned in Section&nbsp;6(e)&nbsp;or 6(f)&nbsp;below, as many copies of the Basic Prospectus, Time of Sale Prospectus, the
Prospectus therein and any supplements and amendments thereto or to the Registration Statement as the Underwriters may reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Before
amending or supplementing the Registration Statement, the Basic Prospectus, the Time of Sale Prospectus or the Prospectus, to furnish
to the Underwriters a copy of each such proposed amendment or supplement and not to file any such proposed amendment or supplement to
which the Underwriters reasonably object in writing, and to file with the Commission within the applicable period specified in Rule&nbsp;424(b)&nbsp;under
the Securities Act any prospectus required to be filed pursuant to such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To
furnish to the Underwriters a copy of each proposed free writing prospectus to be prepared by or on behalf of, used by, or referred to
by the Company and not to use or refer to any proposed free writing prospectus to which the Underwriters reasonably object.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Not
to take any action that would result in an Underwriter or the Company being required to file with the Commission pursuant to Rule&nbsp;433(d)&nbsp;under
the Securities Act a free writing prospectus prepared by or on behalf of the Underwriters that the Underwriters otherwise would not have
been required to file thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
the Time of Sale Prospectus is being used to solicit offers to buy the Shares at a time when the Prospectus is not yet available to prospective
purchasers and any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Time of Sale
Prospectus in order to make the statements therein, in the light of the circumstances, not misleading, or if any event shall occur or
condition exist as a result of which the Time of Sale Prospectus conflicts with the information contained in the Registration Statement
then on file, or if, in the opinion of counsel for the Underwriters, it is necessary to amend or supplement the Time of Sale Prospectus
to comply with applicable law, forthwith to prepare, file with the Commission and furnish, at its own expense, to the Underwriters and
to any dealer upon request, either amendments or supplements to the Time of Sale Prospectus so that the statements in the Time of Sale
Prospectus as so amended or supplemented will not, in the light of the circumstances when the Time of Sale Prospectus is delivered to
a prospective purchaser, be misleading or so that the Time of Sale Prospectus, as amended or supplemented, will no longer conflict with
the Registration Statement, or so that the Time of Sale Prospectus, as amended or supplemented, will comply with applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If,
during such period after the first date of the public offering of the Shares as in the opinion of counsel for the Underwriters the Prospectus
(or in lieu thereof the notice referred to in Rule&nbsp;173(a)&nbsp;of the Securities Act) is required by law to be delivered in connection
with sales by an Underwriter or dealer (the &ldquo;<B>Prospectus Delivery Period</B>&rdquo;), any event shall occur or condition exist
as a result of which it is necessary to amend or supplement the Prospectus in order to make the statements therein, in the light of the
circumstances when the Prospectus (or in lieu thereof the notice referred to in Rule&nbsp;173(a)&nbsp;of the Securities Act) is delivered
to a purchaser, not misleading, or if, in the opinion of counsel for the Underwriters, it is necessary to amend or supplement the Prospectus
to comply with applicable law, forthwith to prepare, file with the Commission and furnish, at its own expense, to the Underwriters and
to the dealers (whose names and addresses the Underwriters will furnish to the Company) to which Shares may have been sold by the Underwriters
and to any other dealers upon request, either amendments or supplements to the Prospectus so that the statements in the Prospectus as
so amended or supplemented will not, in the light of the circumstances when the Prospectus (or in lieu thereof the notice referred to
in Rule&nbsp;173(a)&nbsp;of the Securities Act) is delivered to a purchaser, be misleading or so that the Prospectus, as amended or supplemented,
will comply with applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To
endeavor to qualify the Shares for offer and sale under the securities or Blue Sky laws of such jurisdictions as the Underwriters shall
reasonably request, <I>provided </I>that the Company shall not be required to (i)&nbsp;qualify as a foreign corporation or other entity
or as a dealer in securities in any such jurisdiction where it would not otherwise be required to so qualify, (ii)&nbsp;file any general
consent to service of process in any such jurisdiction or (iii)&nbsp;subject itself to taxation in any such jurisdiction if it is not
otherwise so subject.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To
make generally available (which may be satisfied by filing with the Commission on its Electronic Data Gathering, Analysis and Retrieval
System) to the Company&rsquo;s security holders and to the Underwriters as soon as practicable an earnings statement covering a period
of at least twelve months beginning with the first fiscal quarter of the Company occurring after the date of this Agreement which shall
satisfy the provisions of Section&nbsp;11(a)&nbsp;of the Securities Act and the rules&nbsp;and regulations of the Commission thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Whether
or not the transactions contemplated in this Agreement are consummated or this Agreement is terminated, to pay or cause to be paid all
expenses incident to the performance of its obligations under this Agreement, including: (i)&nbsp;the fees, disbursements and expenses
of the Company&rsquo;s counsel and the Company&rsquo;s accountants in connection with the registration and delivery of the Shares under
the Securities Act and all other fees or expenses in connection with the preparation and filing of the Registration Statement, the Basic
Prospectus, any Preliminary Prospectus, the Time of Sale Prospectus, the Prospectus, any free writing prospectus prepared by or on behalf
of, used by, or referred to by the Company and amendments and supplements to any of the foregoing, including all printing costs associated
therewith, and the mailing and delivering of copies thereof to the Underwriters and dealers, in the quantities hereinabove specified,
(ii)&nbsp;all costs and expenses related to the transfer and delivery of the Shares pursuant to this Agreement, including any transfer
or other taxes payable thereon, (iii)&nbsp;the cost of printing or producing any Blue Sky or Legal Investment memorandum in connection
with the offer and sale of the Shares under state securities laws and all expenses in connection with the qualification of the Shares
for offer and sale under state securities laws as provided in Section&nbsp;6(g)&nbsp;hereof, including filing fees and the reasonable
fees and disbursements of counsel for the Underwriters in connection with such qualification and in connection with the Blue Sky or Legal
Investment memorandum (such fees and expenses of counsel in an aggregate amount not to exceed $5,000), (iv)&nbsp;all filing fees and
the reasonable fees and disbursements of counsel to the Underwriters incurred in connection with the review and qualification of the
offering of the Shares by FINRA (such fees and expenses of counsel in an aggregate amount not to exceed $35,000), (v)&nbsp;costs and
expenses incident to listing the Shares on the Nasdaq Global Market, (vi)&nbsp;the costs and charges of any transfer agent, registrar
or depositary, (vii)&nbsp;the costs and expenses of the Company relating to investor presentations on any &ldquo;road show&rdquo; undertaken
in connection with the marketing of the offering of the Shares (with the Underwriters agreeing to pay all costs and expenses related
to their participation in investor presentations or any &ldquo;road show&rdquo; undertaken in connection with the marketing of the offering
of the Shares), including, without limitation, expenses associated with the preparation or dissemination of any electronic road show,
expenses associated with the production of road show slides and graphics, fees and expenses of any consultants engaged in connection
with the road show presentations with the prior approval of the Company, travel and lodging expenses of the Underwriters and officers
of the Company and any such consultants, and 50% of the cost of any aircraft chartered in connection with the road show with the remaining
50% of the cost of such aircraft to be paid by the Underwriter, (viii)&nbsp;the document production charges and expenses associated with
printing this Agreement, and (ix)&nbsp;all other costs and expenses incident to the performance of the obligations of the Company hereunder
for which provision is not otherwise made in this Section. It is understood, however, that except as provided in this Section, Section&nbsp;8
entitled &ldquo;Indemnity and Contribution&rdquo; and the last paragraph of Section&nbsp;10 below, the Underwriters will pay all of their
costs and expenses, stock transfer taxes payable on resale of any of the Shares by them and any advertising expenses connected with any
offers they may make and all travel and other expenses of the Underwriters or any of their employees incurred by them in connection with
participation in investor presentations on any &ldquo;road show&rdquo; undertaken in connection with the marketing of the offering of
the Shares; <I>provided </I>that the cost of any chartered aircraft shall be paid 50% by the Company as described in clause (vii).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Company will promptly notify the Underwriters if the Company ceases to be an Emerging Growth Company at any time prior to the later of
(i)&nbsp;completion of the distribution of the Shares within the meaning of the Shares Act and (ii)&nbsp;completion of the Restricted
Period (as defined in this Section&nbsp;6).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
at any time during the Prospectus Delivery Period and following the distribution of any Written Testing-the-Waters Communication there
occurred or occurs an event or development as a result of which such Written Testing-the-Waters Communication included or would include
an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein,
in the light of the circumstances existing at that subsequent time, not misleading, the Company will promptly notify the Underwriters
and will promptly amend or supplement, at its own expense, such Written Testing-the-Waters Communication to eliminate or correct such
untrue statement or omission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Company also covenants with each Underwriter that, without the prior written consent of Leerink Partners LLC, it will not, and will not
publicly disclose an intention to, during the period ending 60 days after the date of the Prospectus (the &ldquo;<B>Restricted Period</B>&rdquo;),
(1)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant
any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock
or any securities convertible into or exercisable or exchangeable for Common Stock or (2)&nbsp;enter into any swap or other arrangement
that transfers to another, in whole or in part, any of the economic consequences of ownership of the Common Stock, whether any such transaction
described in clause&nbsp;(1)&nbsp;or (2)&nbsp;above is to be settled by delivery of Common Stock or such other securities, in cash or
otherwise or (3)&nbsp;file any registration statement with the Commission relating to the offering of any shares of Common Stock or any
securities convertible into or exercisable or exchangeable for Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
restrictions contained in the preceding paragraph shall not apply to (A)&nbsp;the Shares to be sold hereunder, (B)&nbsp;the issuance
by the Company of shares of Common Stock upon the exercise of an option or warrant or the conversion of a security outstanding on the
date hereof, (C)&nbsp;grants of options, restricted stock or other equity awards and the issuance of Common Stock or securities convertible
into or exercisable for Common Stock (whether upon the exercise of stock options or otherwise) to employees, officers, directors, advisors,
or consultants of the Company pursuant to the terms of a plan in effect on the date hereof and as described the Time of Sale Prospectus,
provided that the Company shall cause each recipient of such grant to execute and deliver to the Underwriters an agreement substantially
in the form of Exhibit&nbsp;A hereto if such recipient has not already delivered one, (D)&nbsp;the filing of a registration statement
on Form&nbsp;S-8 to register Common Stock issuable pursuant to any employee benefit plans, qualified stock option plans or other employee
compensation plans, described in the Time of Sale Prospectus, (E)&nbsp;Common Stock or any securities convertible into, or exercisable
or exchangeable for, Common Stock, or the entrance into an agreement to issue Common Stock or any securities convertible into, or exercisable
or exchangeable for, Common Stock, in connection with any merger, joint venture, strategic alliances, commercial or other collaborative
transaction or the acquisition or license of the business, property, technology or other assets of another individual or entity or the
assumption of an employee benefit plan in connection with a merger or acquisition; <I>provided </I>that the aggregate number of shares
of Common Stock or any securities convertible into, or exercisable or exchangeable for, Common Stock that the Company may issue or agree
to issue pursuant to this clause (E)&nbsp;shall not exceed 5% of the total outstanding share capital of the Company immediately following
the issuance of the Shares; and provided further, that the recipients of any such shares of Common Stock and securities issued pursuant
to this clause (E)&nbsp;during the 60-day restricted period described above shall enter into an agreement substantially in the form of
Exhibit&nbsp;A hereto on or prior to such issuance, (F)&nbsp;the issuance and sale of shares of Common Stock pursuant to the Equity Distribution
Agreement, dated August&nbsp;13, 2025, by and between the Company and Piper Sandler&nbsp;&amp; Co, as sales agent relating to the Company&rsquo;s
at-the-market sales program as described in the Prospectus, following the 30-day period commencing as of the date hereof; <I>provided</I>
that such shares of Common Stock are sold at a price per share not less than the Public Offering Price, (G)&nbsp;the securities to be
sold in the Concurrent Sanofi Placement, or (H)&nbsp;facilitating the establishment of a trading plan on behalf of a shareholder, officer
or director of the Company pursuant to Rule&nbsp;10b5-1 under the Exchange Act for the transfer of shares of Common Stock; <I>provided</I>
that (i)&nbsp;such plan does not provide for the transfer of Common Stock during the Restricted Period and (ii)&nbsp;to the extent a
public announcement or filing under the Exchange Act, if any, is required of or voluntarily made by the Company regarding the establishment
of such plan, such announcement or filing shall include a statement to the effect that no transfer of Common Stock may be made under
such plan during the Restricted Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Covenants
of the Underwriters. </I> Each Underwriter, severally and not jointly, covenants with the Company not to take any action that would result
in the Company being required to file with the Commission under Rule&nbsp;433(d)&nbsp;a free writing prospectus prepared by or on behalf
of such Underwriter that otherwise would not be required to be filed by the Company thereunder, but for the action of the Underwriter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Indemnity
and Contribution.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Company agrees to indemnify and hold harmless each Underwriter, each person, if any, who controls any Underwriter within the meaning
of either Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act and each affiliate of any Underwriter within the
meaning of Rule&nbsp;405 under the Securities Act from and against any and all losses, claims, damages and liabilities (including, without
limitation, any legal or other expenses reasonably incurred in connection with defending or investigating any such action or claim) that
arise out of, or are based upon, any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement
or any amendment thereof, the Basic Prospectus, any Preliminary Prospectus, the Time of Sale Prospectus or any amendment or supplement
thereto, any issuer free writing prospectus as defined in Rule&nbsp;433(h)&nbsp;under the Securities Act, any Company information that
the Company has filed, or is required to file, pursuant to Rule&nbsp;433(d)&nbsp;under the Securities Act, any road show as defined in
Rule&nbsp;433(h)&nbsp;under the Securities Act (a &ldquo;road show&rdquo;), or the Prospectus or any amendment or supplement thereto,
or any Written Testing-the-Waters Communication, or arise out of, or are based upon, any omission or alleged omission to state therein
a material fact required to be stated therein or necessary to make the statements therein not misleading, except insofar as such losses,
claims, damages or liabilities arise out of, or are based upon, any such untrue statement or omission or alleged untrue statement or
omission made in reliance upon and in conformity with any information relating to any Underwriter furnished to the Company in writing
by such Underwriter expressly for use therein, it being understood and agreed that the only such information furnished by the Underwriters
consists of the information described as such in paragraph (b)&nbsp;below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Each
Underwriter agrees, severally and not jointly, to indemnify and hold harmless the Company, its directors, its officers who sign the Registration
Statement and each person, if any, who controls the Company within the meaning of either Section&nbsp;15 of the Securities Act or Section&nbsp;20
of the Exchange Act to the same extent as the foregoing indemnity from the Company to such Underwriter, but only with reference to information
relating to such Underwriter furnished to the Company in writing by such Underwriter expressly for use in the Registration Statement,
any Preliminary Prospectus, the Time of Sale Prospectus, any issuer free writing prospectus, road show or the Prospectus or any amendment
or supplement thereto, it being understood and agreed that the only such information furnished by any Underwriter consists of the following:
the information relating to market making in the third paragraph under the caption &ldquo;Underwriting,&rdquo; the concession figure
appearing in the fifth paragraph under the caption &ldquo;Underwriting,&rdquo; the information relating to stabilizing transactions contained
in the fourteenth paragraph under the caption &ldquo;Underwriting&rdquo; and the information regarding internet distribution appearing
in the twentieth paragraph under the caption &ldquo;Underwriting.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In
case any proceeding (including any governmental investigation) shall be instituted involving any person in respect of which indemnity
may be sought pursuant to Section&nbsp;8(a)&nbsp;or 8(b), such person (the &ldquo;<B>indemnified party</B>&rdquo;) shall promptly notify
the person against whom such indemnity may be sought (the &ldquo;<B>indemnifying party</B>&rdquo;) in writing and the indemnifying party,
upon request of the indemnified party, shall retain counsel reasonably satisfactory to the indemnified party to represent the indemnified
party and any others the indemnifying party may designate in such proceeding and shall pay the reasonably incurred fees and disbursements
of such counsel related to such proceeding. In any such proceeding, any indemnified party shall have the right to retain its own counsel,
but the fees and expenses of such counsel shall be at the expense of such indemnified party unless (i)&nbsp;the indemnifying party and
the indemnified party shall have mutually agreed to the retention of such counsel or (ii)&nbsp;the named parties to any such proceeding
(including any impleaded parties) include both the indemnifying party and the indemnified party and representation of both parties by
the same counsel would be inappropriate due to actual or potential differing interests between them. It is understood that the indemnifying
party shall not, in respect of the legal expenses of any indemnified party in connection with any proceeding or related proceedings in
the same jurisdiction, be liable for the fees and expenses of more than one separate firm (in addition to any local counsel) for all
such indemnified parties and that all such fees and expenses shall be reimbursed as they are incurred. Such firm shall be designated
in writing by the Underwriters, in the case of parties indemnified pursuant to Section&nbsp;8(a), and by the Company, in the case of
parties indemnified pursuant to Section&nbsp;8(b). The indemnifying party shall not be liable for any settlement of any proceeding effected
without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party
agrees to indemnify the indemnified party from and against any loss or liability by reason of such settlement or judgment. Notwithstanding
the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party
for fees and expenses of counsel as contemplated by the second and third sentences of this paragraph, the indemnifying party agrees that
it shall be liable for any settlement of any proceeding effected without its written consent if (i)&nbsp;such settlement is entered into
more than 30 days after receipt by such indemnifying party of the aforesaid request and (ii)&nbsp;such indemnifying party shall not have
reimbursed the indemnified party in accordance with such request prior to the date of such settlement. No indemnifying party shall, without
the prior written consent of the indemnified party, effect any settlement of any pending or threatened proceeding in respect of which
any indemnified party is or could have been a party and indemnity could have been sought hereunder by such indemnified party, unless
such settlement (i)&nbsp;includes an unconditional release of such indemnified party from all liability on claims that are the subject
matter of such proceeding and (ii)&nbsp;does not include a statement as to or an admission of fault, culpability or a failure to act
by or on behalf of any indemnified party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To
the extent the indemnification provided for in Section&nbsp;8(a)&nbsp;or 8(b)&nbsp;is unavailable to an indemnified party or insufficient
in respect of any losses, claims, damages or liabilities referred to therein, then each indemnifying party under such paragraph, in lieu
of indemnifying such indemnified party thereunder, shall contribute to the amount paid or payable by such indemnified party as a result
of such losses, claims, damages or liabilities (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received
by the Company on the one hand and the Underwriters on the other hand from the offering of the Shares or (ii)&nbsp;if the allocation
provided by clause&nbsp;8(d)(i)&nbsp;above is not permitted by applicable law, in such proportion as is appropriate to reflect not only
the relative benefits referred to in clause&nbsp;8(d)(i)&nbsp;above but also the relative fault of the Company on the one hand and of
the Underwriters on the other hand in connection with the statements or omissions that resulted in such losses, claims, damages or liabilities,
as well as any other relevant equitable considerations. The relative benefits received by the Company on the one hand and the Underwriters
on the other hand in connection with the offering of the Shares shall be deemed to be in the same respective proportions as the net proceeds
from the offering of the Shares (before deducting expenses) received by the Company and the total underwriting discounts and commissions
received by the Underwriters, in each case as set forth in the table on the cover of the Prospectus, bear to the aggregate Public Offering
Price. The relative fault of the Company on the one hand and the Underwriters on the other hand shall be determined by reference to,
among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a
material fact relates to information supplied by the Company or by the Underwriters and the parties&rsquo; relative intent, knowledge,
access to information and opportunity to correct or prevent such statement or omission. The Underwriters&rsquo; respective obligations
to contribute pursuant to this Section&nbsp;8 are several in proportion to the respective number of Shares they have purchased hereunder,
and not joint.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Company and the Underwriters agree that it would not be just or equitable if contribution pursuant to this Section&nbsp;8 were determined
by <I>pro rata</I> allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation
that does not take account of the equitable considerations referred to in Section&nbsp;8(d). The amount paid or payable by an indemnified
party as a result of the losses, claims, damages and liabilities referred to in Section&nbsp;8(d)&nbsp;shall be deemed to include, subject
to the limitations set forth above, any legal or other expenses reasonably incurred by such indemnified party in connection with investigating
or defending any such action or claim. Notwithstanding the provisions of this Section&nbsp;8, no Underwriter shall be required to contribute
any amount in excess of the amount by which the total price at which the Shares underwritten by it and distributed to the public were
offered to the public exceeds the amount of any damages that such Underwriter has otherwise been required to pay by reason of such untrue
or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of
Section&nbsp;11(f)&nbsp;of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent
misrepresentation. The remedies provided for in this Section&nbsp;8 are not exclusive and shall not limit any rights or remedies which
may otherwise be available to any indemnified party at law or in equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
indemnity and contribution provisions contained in this Section&nbsp;8 and the representations, warranties and other statements of the
Company contained in this Agreement shall remain operative and in full force and effect regardless of (i)&nbsp;any termination of this
Agreement, (ii)&nbsp;any investigation made by or on behalf of any Underwriter, any person controlling any Underwriter or any affiliate
of any Underwriter or by or on behalf of the Company, its officers or directors or any person controlling the Company and (iii)&nbsp;acceptance
of and payment for any of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Termination.
</I>The Underwriters may terminate this Agreement by notice given by the Underwriters to the Company, if after the execution and delivery
of this Agreement and prior to or on the Closing Date or any Option Closing Date, as the case may be, (i)&nbsp;trading generally shall
have been suspended or materially limited on, or by, as the case may be, any of the New York Stock Exchange, the NYSE MKT, the Nasdaq
Global Market, the Chicago Board of Options Exchange, the Chicago Mercantile Exchange or the Chicago Board of Trade, (ii)&nbsp;trading
of any securities of the Company shall have been suspended on any exchange or in any over-the-counter market, (iii)&nbsp;a material disruption
in securities settlement, payment or clearance services in the United States shall have occurred, (iv)&nbsp;any moratorium on commercial
banking activities shall have been declared by Federal or New York State authorities or (v)&nbsp;there shall have occurred any outbreak
or escalation of hostilities, or any change in financial markets or any calamity or crisis that, in the Underwriters&rsquo; judgment,
is material and adverse and which, singly or together with any other event specified in this clause&nbsp;(v), makes it, in the Underwriters&rsquo;
judgment, impracticable or inadvisable to proceed with the offer, sale or delivery of the Shares on the terms and in the manner contemplated
in the Time of Sale Prospectus or the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Effectiveness;
Defaulting Underwriters. </I>This Agreement shall become effective upon the execution and delivery hereof by the parties hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">If
on the Closing Date or an Option Closing Date, as the case may be, any one or more of the Underwriters shall fail or refuse to purchase
Shares that it has or they have agreed to purchase hereunder on such date, and the aggregate number of Shares which such defaulting Underwriter
or Underwriters agreed but failed or refused to purchase is not more than one-tenth of the aggregate number of the Shares to be purchased
on such date, the other Underwriters shall be obligated severally in the proportions that the number of Firm Shares set forth opposite
their respective names in Schedule I bears to the aggregate number of Firm Shares set forth opposite the names of all such non-defaulting
Underwriters, or in such other proportions as the Underwriters may specify, to purchase the Firm Shares which such defaulting Underwriter
or Underwriters agreed but failed or refused to purchase on such date; provided that in no event shall the number of Firm Shares that
any Underwriter has agreed to purchase pursuant to this Agreement be increased pursuant to this Section&nbsp;10 by an amount in excess
of one-ninth of such number of Firm Shares without the written consent of such Underwriter. If, on the Closing Date, any Underwriter
or Underwriters shall fail or refuse to purchase Firm Shares and the aggregate number of Firm Shares with respect to which such default
occurs is more than one-tenth of the aggregate number of Firm Shares to be purchased on such date, and arrangements satisfactory to the
Underwriters and the Company for the purchase of such Firm Shares are not made within 36 hours after such default, this Agreement shall
terminate without liability on the part of any non-defaulting Underwriter or the Company. In any such case either the Underwriters or
the Company shall have the right to postpone the Closing Date, but in no event for longer than seven days, in order that the required
changes, if any, in the Registration Statement, in the Time of Sale Prospectus, in the Prospectus or in any other documents or arrangements
may be effected. If, on an Option Closing Date, any Underwriter or Underwriters shall fail or refuse to purchase Additional Shares and
the aggregate number of Additional Shares with respect to which such default occurs is more than one-tenth of the aggregate number of
Additional Shares to be purchased on such Option Closing Date, the non-defaulting Underwriters shall have the option to (i)&nbsp;terminate
their obligation hereunder to purchase the Additional Shares to be sold on such Option Closing Date or (ii)&nbsp;purchase not less than
the number of Additional Shares that such non-defaulting Underwriters would have been obligated to purchase in the absence of such default.
Any action taken under this paragraph shall not relieve any defaulting Underwriter from liability in respect of any default of such Underwriter
under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">If
this Agreement shall be terminated by the Underwriters, or any of them, because of any failure or refusal on the part of the Company
to comply with the terms or to fulfill any of the conditions of this Agreement, or if for any reason the Company shall be unable to perform
its obligations under this Agreement other than by reason of a default by the Underwriters or following termination of this Agreement
pursuant to clauses (i), (iii), (iv)&nbsp;or (v)&nbsp;of Section&nbsp;9, the Company will reimburse the Underwriters or such Underwriters
as have so terminated this Agreement with respect to themselves, severally, for all out-of-pocket expenses (including the fees and disbursements
of their counsel) reasonably incurred by such Underwriters in connection with this Agreement or the offering contemplated hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">11.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Entire
Agreement. </I>(a)&nbsp;This Agreement, together with any contemporaneous written agreements and any prior written agreements (to the
extent not superseded by this Agreement) that relate to the offering of the Shares, represents the entire agreement between the Company
and the Underwriters with respect to the preparation of any Preliminary Prospectus, the Basic Prospectus, the Time of Sale Prospectus,
the Prospectus, the conduct of the offering, and the purchase and sale of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Company acknowledges that in connection with the offering of the Shares: (i)&nbsp;the Underwriters have acted at arm&rsquo;s length,
are not agents of, and owe no fiduciary duties to, the Company or any other person, (ii)&nbsp;the Underwriters owe the Company only those
duties and obligations set forth in this Agreement, any contemporaneous written agreements and prior written agreements (to the extent
not superseded by this Agreement), if any, (iii)&nbsp;the Underwriters may have interests that differ from those of the Company, and
(iv)&nbsp;none of the activities of the Underwriters in connection with the transactions contemplated herein constitutes a recommendation,
investment advice, or solicitation of any action by the Underwriters with respect to any entity or natural person. The Company waives
to the full extent permitted by applicable law any claims it may have against the Underwriters arising from an alleged breach of fiduciary
duty in connection with the offering of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">12.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Recognition
of the U.S. Special Resolution Regimes.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In
the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer
from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent
as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation,
were governed by the laws of the United States or a state of the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In
the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under
a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to
be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement
were governed by the laws of the United States or a state of the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">For
purposes of this Section&nbsp;a &ldquo;<B>BHC Act Affiliate</B>&rdquo; has the meaning assigned to the term &ldquo;affiliate&rdquo; in,
and shall be interpreted in accordance with, 12 U.S.C. &sect; 1841(k). &ldquo;<B>Covered Entity</B>&rdquo; means any of the following:
(i)&nbsp;a &ldquo;covered entity&rdquo; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 252.82(b); (ii)&nbsp;a
 &ldquo;covered bank&rdquo; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 47.3(b); or (iii)&nbsp;a
 &ldquo;covered FSI&rdquo; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 382.2(b). &ldquo;<B>Default
Right</B>&rdquo; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &sect;&sect; 252.81,
47.2 or 382.1, as applicable. &ldquo;<B>U.S. Special Resolution Regime</B>&rdquo; means each of (i)&nbsp;the Federal Deposit Insurance
Act and the regulations promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act
and the regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">13.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Counterparts.
</I>This Agreement may be signed in two or more counterparts, which may be delivered via facsimile, electronic mail (including any electronic
signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act
or other applicable law, e.g., www.docusign.com), each of which shall be an original, with the same effect as if the signatures thereto
and hereto were upon the same instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">14.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Applicable
Law. </I>This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">15.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Headings.
</I>The headings of the sections of this Agreement have been inserted for convenience of reference only and shall not be deemed a part
of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">16.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Notices.
</I>All communications hereunder shall be in writing and effective only upon receipt and if to the Underwriters shall be delivered, mailed
or sent to (i)&nbsp;Leerink Partners LLC at 1301 Avenue of the Americas, 5th Floor, New York, New York 10009, Attention: Stuart Nayman
and Oppenheimer&nbsp;&amp; Co. Inc., 85 Broad Street, 23rd Floor New York, NY 10004, Attn: General Counsel; and (ii)&nbsp;if to the Company
shall be delivered, mailed or sent to Immuneering Corporation, 245 Main Street, Second Floor, Cambridge, Massachusetts 02142, Attention:
General Counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">[<I>Signature Page&nbsp;Follows</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
<TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Very truly yours,</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
<TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
<TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">IMMUNEERING CORPORATION</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
<TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
<TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Benjamin J. Zeskind, Ph.D.</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 10pt; width: 3%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 10pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
<TD STYLE="font-size: 10pt; width: 42%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benjamin J. Zeskind,
Ph.D.</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
<TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President and Chief Executive Officer</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">Accepted as of the date hereof</FONT></P>

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">LEERINK PARTNERS LLC</FONT></P>



<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-right: 0.7pt; padding-left: 0.7pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding-right: 0.7pt; padding-left: 0.7pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Jon Civitarese</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-right: 0.7pt; padding-left: 0.7pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.7pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="padding-right: 0.7pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jon Civitarese</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-right: 0.7pt; padding-left: 0.7pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.7pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="padding-right: 0.7pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Senior
    Managing Director</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-right: 0.7pt; padding-left: 0.7pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 0.7pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD COLSPAN="3" STYLE="padding-right: 0.7pt; padding-left: 0.7pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">OPPENHEIMER&nbsp;&amp;
    CO. INC.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-right: 0.7pt; padding-left: 0.7pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 0.7pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; padding-right: 0.5pt; padding-left: 0.5pt"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt"><FONT STYLE="font-size: 10pt">/s/
    Michael A. Margolis, R.Ph.&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; padding-right: 0.5pt; padding-left: 0.5pt; width: 3%"></TD>
    <TD STYLE="font-size: 10pt; padding-right: 0.5pt; padding-left: 0.5pt; width: 5%"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-right: 0.5pt; padding-left: 0.5pt; width: 42%"><FONT STYLE="font-size: 10pt">Michael A. Margolis, R.Ph.</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; padding-right: 0.5pt; padding-left: 0.5pt"></TD>
    <TD STYLE="font-size: 10pt; padding-right: 0.5pt; padding-left: 0.5pt"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-right: 0.5pt; padding-left: 0.5pt"><FONT STYLE="font-size: 10pt">Head of Healthcare Investment Banking</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 10pt"><B>SCHEDULE I</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">Underwriter</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">Number
    of Firm<BR> Shares Purchased</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 81%; text-align: left"><FONT STYLE="font-size: 10pt">Leerink Partners
    LLC</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-size: 10pt">12,134,345</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Oppenheimer&nbsp;&amp;
    Co. Inc</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">6,825,569</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">Total</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">18,959,914</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Schedule I-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 10pt"><B>SCHEDULE II</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Time of Sale
Prospectus</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 5%"><FONT STYLE="font-size: 10pt">1.</FONT></TD><TD STYLE="font-size: 10pt; width: 95%"><FONT STYLE="font-size: 10pt">Preliminary Prospectus filed on September&nbsp;24,
                             2025</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">2.</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">The issuer free writing prospectus, dated as of September&nbsp;24, 2025</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">3.</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Pricing Information:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 5%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 45%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of Firm
    Shares:</FONT></TD>
    <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,959,914</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of Additional Shares:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up to 2,843,987</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public Offering Price:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$9.23</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Schedule II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 10pt"><B>SCHEDULE III</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Written Testing-the-Waters
Communications</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">1.</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">None</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Schedule III-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 10pt"><B>EXHIBIT&nbsp;A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>FORM&nbsp;OF
LOCK-UP LETTER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">___________________,
2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Leerink Partners LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">53 State Street</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">40th Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Boston, Massachusetts 02109</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Oppenheimer&nbsp;&amp; Co. Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">85 Broad Street, 23rd Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">New York, NY 10004</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Ladies and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The undersigned
understands that Leerink Partners LLC and Oppenheimer&nbsp;&amp; Co. Inc. (the &ldquo;<B>Underwriter</B>&rdquo;) proposes to enter into
an Underwriting Agreement (the &ldquo;<B>Underwriting Agreement</B>&rdquo;) with Immuneering Corporation, a Delaware corporation (the
 &ldquo;<B>Company</B>&rdquo;), providing for the offering (the &ldquo;<B>Public Offering</B>&rdquo;) by the Underwriters of shares (the
 &ldquo;<B>Shares</B>&rdquo;) of its Class&nbsp;A common stock, $0.001 par value per share (the &ldquo;<B>Common Stock</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">To induce the Underwriters
that may participate in the Public Offering to continue their efforts in connection with the Public Offering, the undersigned hereby
agrees that, without the prior written consent of Leerink Partners LLC, it will not, and will not publicly disclose an intention to,
during the period commencing on the date hereof and ending 60 days after the date of the final prospectus (the &ldquo;<B>Restricted Period</B>&rdquo;)
relating to the Public Offering (the &ldquo;<B>Prospectus</B>&rdquo;), (1)&nbsp;offer, pledge, sell, contract to sell, sell any option
or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise
transfer or dispose of, directly or indirectly, any shares of Common Stock beneficially owned (as such term is used in Rule&nbsp;13d-3
of the Securities Exchange Act of 1934, as amended (the &ldquo;<B>Exchange Act</B>&rdquo;)), by the undersigned or any other securities
so owned convertible into or exercisable or exchangeable for Common Stock or (2)&nbsp;enter into any swap or other arrangement that transfers
to another, in whole or in part, any of the economic consequences of ownership of the Common Stock, whether any such transaction described
in clause&nbsp;(1)&nbsp;or (2)&nbsp;above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise.
The undersigned acknowledges and agrees that the foregoing precludes the undersigned from engaging in any hedging or other transaction
designed or intended, or which could reasonably be expected to lead to or result in, a sale or disposition of any shares of Common Stock,
or any securities convertible into or exercisable or exchangeable for Common Stock, even if any such sale or disposition transaction
or transactions would be made or executed by or on behalf of someone other than the undersigned.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The foregoing restrictions
(including the transactions described in clauses (1)&nbsp;and (2)&nbsp;of the preceding paragraph) shall not apply to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">transactions (including any swap, hedge,
                                            derivative or other synthetic arrangement) or public announcement relating to shares of Common
                                            Stock or other securities acquired (i)&nbsp;in the Public Offering, or (ii)&nbsp;in open
                                            market or other transactions after the completion of the Public Offering or that otherwise
                                            do not involve or relate to shares of Common Stock or other securities owned by the undersigned
                                            prior to the Public Offering, <I>provided</I> that no filing under Section&nbsp;16(a)&nbsp;of
                                            the Exchange Act shall be required or shall be voluntarily made during the Restricted Period
                                            in connection with subsequent sales of Common Stock or other securities acquired in the Public
                                            Offering or in such open market or other transactions (it being understood that the undersigned
                                            may make required filings on Schedule 13D, Schedule 13F, Schedule 13G and any amendments
                                            thereto during the Restricted Period);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">transfers, dispositions or distributions
                                            of shares of Common Stock or any security convertible into or exercisable or exchangeable
                                            for Common Stock (i)&nbsp;as a bona fide gift or charitable contribution, (ii)&nbsp;by will
                                            or intestacy or to a trust whose beneficiaries consist exclusively of one or more of the
                                            undersigned and/or any immediate family member, (iii)&nbsp;to limited partners, general partners,
                                            members, stockholders or holders of similar equity interests in the undersigned or (iv)&nbsp;to
                                            another corporation, partnership, limited liability company, trust or other business entity
                                            that is an affiliate (as defined in Rule&nbsp;405 promulgated under the Securities Act of
                                            1933, as amended) of the undersigned, or to any investment fund or other entity controlling,
                                            controlled by, managing, managed by, or under common control or common investment management
                                            with, the undersigned or affiliates of the undersigned (including, for the avoidance of doubt,
                                            where the undersigned is a partnership, to its general partner or a successor partnership
                                            or fund, or any other funds managed by such partnership); <I>provided</I> that (A)&nbsp;each
                                            transferee, donee or distributee shall sign and deliver a lock-up agreement substantially
                                            in the form of this agreement and (B)&nbsp;no filing under Section&nbsp;16(a)&nbsp;of the
                                            Exchange Act, reporting a reduction in beneficial ownership of shares of Common Stock, shall
                                            be voluntarily made during the Restricted Period and, if required, any filing under Section&nbsp;16(a)&nbsp;of
                                            the Exchange Act shall indicate in the footnotes thereto the nature of the transaction (it
                                            being understood that the undersigned may make required filings on Schedule 13D, Schedule
                                            13F, Schedule 13G and any amendments thereto during the Restricted Period);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(c)</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">transfers of Common Stock or any security
                                            convertible into or exercisable or exchangeable for Common Stock by operation of law pursuant
                                            to a qualified domestic order or other court order or in connection with a divorce settlement;
                                            provided that (i)&nbsp;any filing under Section&nbsp;16(a)&nbsp;of the Exchange Act made
                                            during the Restricted Period shall clearly indicate in the footnotes thereto that (A)&nbsp;the
                                            filing relates to the circumstances described in this clause (c)&nbsp;and (B)&nbsp;no securities
                                            were sold by the undersigned, and (ii)&nbsp;the undersigned does not otherwise voluntarily
                                            effect any other public filing or report regarding such transfers during the Restricted Period
                                            (it being understood that the undersigned may make required filings on Schedule 13D, Schedule
                                            13F, Schedule 13G and any amendments thereto during the Restricted Period);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(d)</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">the receipt by the undersigned from
                                            the Company of shares of Common Stock upon the transfer or disposition of shares of Common
                                            Stock or any securities convertible into Common Stock to the Company upon a vesting or settlement
                                            event of the Company&rsquo;s securities or upon the exercise of options to purchase the Company&rsquo;s
                                            securities on a &ldquo;cashless&rdquo; or &ldquo;net exercise&rdquo; basis to the extent
                                            permitted by the instruments representing such options described in the Prospectus or the
                                            documents incorporated therein, provided that (i)&nbsp;the shares received upon exercise
                                            or settlement of the option are subject to the terms of this letter, (ii)&nbsp;no public
                                            disclosure or filing under Section&nbsp;16(a)&nbsp;of the Exchange Act shall be voluntarily
                                            made during the Restricted Period and (iii)&nbsp;to the extent a filing under Section&nbsp;16(a)&nbsp;of
                                            the Exchange Act is required during the Restricted Period as a result of transfers pursuant
                                            to this clause (d), it shall clearly indicate that (A)&nbsp;the filing relates to the circumstances
                                            described in this clause (d), including that the securities remain subject to the terms of
                                            this letter and (B)&nbsp;no securities were sold by the undersigned other than pursuant to
                                            this clause (d)&nbsp;(it being understood that the undersigned may make required filings
                                            on Schedule 13D, Schedule 13F, Schedule 13G and any amendments thereto during the Restricted
                                            Period);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(e)</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">transfers to the Company in connection
                                            with the repurchase of Common Stock in connection with the termination of the undersigned&rsquo;s
                                            employment with the Company pursuant to contractual agreements with the Company, provided
                                            that no public disclosure or filing under Section&nbsp;16(a)&nbsp;of the Exchange Act shall
                                            be voluntarily made during the Restricted Period and, if required, any public disclosure
                                            or filing under Section&nbsp;16(a)&nbsp;of the Exchange Act shall indicate in the footnotes
                                            thereto the nature of the transaction (it being understood that the undersigned may make
                                            required filings on Schedule 13D, Schedule 13F, Schedule 13G and any amendments thereto during
                                            the Restricted Period);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(f)</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">the establishment of a trading plan
                                            on behalf of a shareholder, officer or director of the Company pursuant to Rule&nbsp;10b5-1
                                            under the Exchange Act for the transfer of shares of Common Stock, <I>provided</I> that (i)&nbsp;such
                                            plan does not provide for the transfer of Common Stock during the Restricted Period and (ii)&nbsp;to
                                            the extent a public announcement or filing under the Exchange Act, if any, is required of
                                            or voluntarily made by or on behalf of the undersigned or the Company regarding the establishment
                                            of such plan, such announcement or filing shall include a statement to the effect that no
                                            transfer of Common Stock may be made under such plan during the Restricted Period; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(g)</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">transfers pursuant to a bona fide third-party
                                            tender offer for all outstanding Common Stock of the Company, merger, consolidation or other
                                            similar transaction made to all holders of the Company&rsquo;s securities involving a change
                                            of control of the Company and approved by the Company&rsquo;s board of directors (including,
                                            without limitation, the entering into any lock-up, voting or similar agreement pursuant to
                                            which the undersigned may agree to transfer, sell, tender or otherwise dispose of Common
                                            Stock or other such securities in connection with such transaction, or vote any Common Stock
                                            or other such securities in favor of any such transaction); provided that in the event that
                                            such tender offer, merger, consolidation or other such transaction is not completed, such
                                            securities held by the undersigned shall remain subject to the provisions of this agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">In addition, the
undersigned agrees that, without the prior written consent of Leerink Partners LLC, it will not, during the Restricted Period, make any
demand for or exercise any right with respect to, the registration of any shares of Common Stock or any security convertible into or
exercisable or exchangeable for Common Stock. The undersigned also agrees and consents to the entry of stop transfer instructions with
the Company&rsquo;s transfer agent and registrar against the transfer of the undersigned&rsquo;s shares of Common Stock except in compliance
with the foregoing restrictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">For purposes of
this agreement, (i)&nbsp;&ldquo;immediate family member&rdquo; shall mean any relationship by blood, marriage or adoption, not more remote
than first cousin, and (ii)&nbsp;&ldquo;change of control&rdquo; shall mean the consummation of any bona fide third party tender offer,
merger, amalgamation, consolidation or other similar transaction the result of which is that any &ldquo;person&rdquo; (as defined in
Section&nbsp;13(d)(3)&nbsp;of the Exchange Act), or group of persons, other than the Company, becomes the beneficial owner (as defined
in Rules&nbsp;13d-3 and 13d-5 of the Exchange Act) of greater than 50% of the total voting power of the voting stock of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The undersigned
understands that the Company and the Underwriters are relying upon this agreement in proceeding toward consummation of the Public Offering.
The undersigned further understands that this agreement is irrevocable and shall be binding upon the undersigned&rsquo;s heirs, legal
representatives, successors and assigns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The undersigned
acknowledges and agrees that the Underwriters have not provided any recommendation or investment advice nor have the Underwriters solicited
any action from the undersigned with respect to the Public Offering of the Common Stock and the undersigned has consulted their own legal,
accounting, financial, regulatory and tax advisors to the extent deemed appropriate. The undersigned further acknowledges and agrees
that, although the Underwriters may provide certain Regulation Best Interest and Form&nbsp;CRS disclosures or other related documentation
to you in connection with the Public Offering, the Underwriters are not making a recommendation to&nbsp;you to participate in the Public
Offering or sell any Common Stock at the price determined in the Public Offering, and nothing set forth in such disclosures or documentation
is intended to suggest that any Underwriter is making such a recommendation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Whether or not the
Public Offering actually occurs depends on a number of factors, including market conditions. Any Public Offering will only be made pursuant
to an Underwriting Agreement, the terms of which are subject to negotiation between the Company and the Underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The undersigned
understands that, if (i)&nbsp;the Underwriters, on the one hand, or the Company, on the other hand, informs the other in writing, prior
to the execution of the Underwriting Agreement, that it has determined not to proceed with the Public Offering, (ii)&nbsp;the Underwriting
Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated prior to payment for and delivery
of the securities to be sold thereunder, (iii)&nbsp;the Underwriting Agreement is not executed on or before September&nbsp;30, 2025,
then, in each case, this agreement shall automatically, and without any action on the part of any other party, be of no further force
and effect, and the undersigned shall be automatically released from all obligations under this agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">This agreement shall
be governed by and construed in accordance with the laws of the State of New York.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">[SIGNATURE PAGE
FOLLOWS]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%; padding-right: 5.75pt; padding-left: 0.25in; font-size: 10pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.75pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.75pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name)</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.75pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.75pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.75pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<!-- Field: Page; Sequence: 41; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>tm2526946d1_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 5.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 72%; vertical-align: bottom">&nbsp;</TD>
<TD STYLE="white-space: nowrap; text-align: left; width: 28%">200 Clarendon Street<BR>
 Boston, Massachusetts 02116<BR>
 Tel: +1.617.948.6000 Fax: +1.617.948.6001<BR>
 www.lw.com &nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD ROWSPAN="3"><IMG SRC="tm2526946d1_ex5-1img001.jpg" ALT="">&nbsp;</TD>
<TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FIRM / AFFILIATE OFFICES&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Austin</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Milan</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beijing</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Munich</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 72%">&nbsp;</TD>
<TD STYLE="width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Boston</FONT></TD>
<TD STYLE="width: 16%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New York</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brussels</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Orange County</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chicago</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paris</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dubai</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Riyadh</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 25, 2025</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D&uuml;sseldorf</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">San Diego</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Frankfurt</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">San Francisco</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hamburg</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Seoul</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Silicon Valley</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Houston</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Singapore</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">London</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel Aviv</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Los Angeles</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tokyo</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Madrid</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Washington, D.C.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Immuneering Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">245 Main Street</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Second Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cambridge, Massachusetts 02142</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">Re:</TD><TD><U>Registration Statement on Form S-3 (Registration No. 333-289589); 21,803,901 shares of Class A common stock, par value $0.001 per
share</U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">To the addressee set forth above:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have acted as special counsel to Immuneering Corporation, a Delaware
corporation (the &ldquo;<B><I>Company</I></B>&rdquo;), in connection with the proposed issuance of up to 21,803,901 shares of Class A
common stock of the Company, par value $0.001 per share (the &ldquo;<B><I>Shares</I></B>&rdquo;). The Shares are included in a registration
statement on Form S-3 under the Securities Act of 1933, as amended (the &ldquo;<B><I>Act</I></B>&rdquo;), filed with the Securities and
Exchange Commission (the &ldquo;<B><I>Commission</I></B>&rdquo;) on August 13, 2025 (Registration No. 333-289589) (the &ldquo;<B><I>Registration
Statement</I></B>&rdquo;), and are being offered pursuant to a base prospectus dated August 20, 2025 (the &ldquo;<B><I>Base Prospectus</I></B>&rdquo;)
and a prospectus supplement dated September 24, 2025 filed with the Commission pursuant to Rule 424(b) under the Act (together with the
Base Prospectus, the &ldquo;<B><I>Prospectus</I></B>&rdquo;). The Shares are being sold pursuant to an underwriting agreement dated September
24, 2025 by and among the Company and Leerink Partners LLC and Oppenheimer &amp; Co. Inc., as underwriters (the &ldquo;<B><I>Underwriting
Agreement</I></B>&rdquo;). This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K under
the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or related Prospectus,
other than as expressly stated herein with respect to the issue of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As such counsel, we have examined such matters
of fact and questions of law as we have considered appropriate for purposes of this letter. With your consent, we have relied upon certificates
and other assurances of officers of the Company and others as to factual matters without having independently verified such factual matters.
We are opining herein as to the General Corporation Law of the State of Delaware, and we express no opinion with respect to any other
laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>September 25, 2025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Page 2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"><IMG SRC="tm2526946d1_ex5-1img002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the foregoing and the other matters set forth herein, it is our opinion that, as of the date hereof, </FONT>when the Shares shall have
been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the purchasers, and have been
issued by the Company against payment therefor (not less than par value) in the circumstances contemplated by the Underwriting Agreement,
the issue and sale of the Shares will have been duly authorized by all necessary corporate action of the Company, and the Shares will
be validly issued, fully paid and nonassessable. In rendering the foregoing opinion, we have assumed that the Company will comply with
all applicable notice requirements regarding uncertificated shares provided in the General Corporation Law of the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
opinion is for your benefit in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely
upon it pursuant to the applicable provisions of the Act. We consent to your filing this opinion as an exhibit to the </FONT>Company&rsquo;s
Form 8-K dated September 25, 2025, and to the reference to our firm in the Prospectus under the heading &ldquo;Legal Matters.&rdquo; In
giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act
or the rules and regulations of the Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely,</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    LATHAM &amp; WATKINS LLP</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.5in"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>imrx-20250924.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWayG6bOdzZR+yYkxtmBwbblq/yklkGdRdyQfPWdWYXgE -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:IMRX="http://immuneering.com/20250924" elementFormDefault="qualified" targetNamespace="http://immuneering.com/20250924">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://immuneering.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="imrx-20250924_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="imrx-20250924_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>imrx-20250924_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>imrx-20250924_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="imrx-20250924.xsd#Cover" roleURI="http://immuneering.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://immuneering.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tm2526946d1_ex5-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2526946d1_ex5-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  > 1D# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W74M2M-(L
M);Z^F\FVBQO?:6QD@#@ GJ13K&^MM2LHKRTD\RWE7<C[2,CZ'FN4^*__ "33
M5_\ MC_Z.2K?P[_Y)_HO_7O_ %-9\SY^7R.MT(_5E6Z\UOPN=167>^(M*T[5
M+?3;J[$=W<X\J/8QW9.!R!@<^M:E>">+K6]\0:OXB\3V<AV:+<Q0PG/9,[\?
M1L-^)I59N*T+P6&C7FU-V7ZO1?B>[S31P0O-*VV-%+,<9P!R:YG_ (61X3_Z
M"P_\!Y?_ (FMK3;R#6]#MKL*&@NX%<J?1AR/UQ7EOQ'\.:-I>K>%HK'3K>W2
MXO=DP1<;UW)P?S/YT5)2BN:)6#H4JM7V56Z>NUNB=]_0],T;Q+I'B S#2[O[
M08<>9^[=<9SC[P'H:L66LV&HW5W;6EQYDUH^R==C#8W/'(YZ'I46EZ%I>C>8
M=-L8;7S<;_*7&[&<9_.O./#'B72/#_C+Q@NJ7J6QFO@8PRD[L%L]![BAR<;<
MQ$*$:RFZ2>B5EUWMT/3+W6;#3[NTM;JX\N:\?9 NQCO/'&0,#J.M72P'4UY-
MXD\2:1X@\;^#_P"R[U+DPWI\S:I&W)7'4>QKU661(H7DD8*B L2>P%5&7,V1
M7P[I1@VG>2V^=B@OB/26UPZ,+L?V@!DP^6WINZXQT]ZT]P]:^?%-[#?67Q%8
ML()M8D#Y/(A)"C] Z_E7OZ$.H(.01D$5-.;E>_\ 2-,9AE0Y>5WNM?5;K\2A
M/XBTFVUF+2)KL+?2@%(O+8YSG'.,=CWJU?ZA:Z992WEY+Y5O$,N^TG Z= ,U
MX;XX:Y/Q U?7;8MC1);3./?']:[?XEWAU70-(T>R?+ZW<QJI'>/AB?S*U*JN
MTO+^OS-Y8"*=*STEOY=7^!W&F:M8ZQ8I>V$_G6[DA7VE<D'!X(!JYN'K7GOP
MA8IX5N[%CEK*_EB_D?YDU;UKQ3<P>*H]-L;F'$)B#P&(NT[.^&0,#A2J_-^/
MH*N,[Q4F<U7#-5YTH:V_(Z^^U"UTVSEN[N7RX(AEWVDX'T S1;ZA:W5A'?0R
M[K:2/S5?:1E<9S@\U2U"&WU[P_?VL;+)'<12P$^C<J?R.?RKSC1/$!M?@7>N
MSD7%HDMG[AF;"_D''Y42GROY!2PWM(76_,E]YZ7I&OZ9KUN\^F77GQ(VQFV,
MN#C/\0'K2P:[IMSK%QI,5SNOK==TL6QAM''?&.X[UYC\*89] \0ZAH5R"C7%
ME!>*I[-M&[]6Q^%:WPTMS?ZQXD\2O@K>7CQ0D]=BDG^14?A40J.27<WKX2G3
M=1I^ZDK>=]OU.ZU76M/T2T%UJ-QY$)<(&V,W)SQ@ GL:LV]U#=6T5Q"^^*5
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49"JXR?UK8HHJK6)E)RDY2W9__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tm2526946d1_ex5-1img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2526946d1_ex5-1img002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  8 ,,# 2(  A$! Q$!_\0
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88Z-$6-%1%"HH 4 < 4ZBBJ, HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Sep. 24, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 24,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Immuneering
Corporation<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001790340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-1976972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">245
Main St.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Second
Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">500-8080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class
                                            A Common Stock,  par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IMRX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2526946d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>imrx-20250924.xsd</File>
    <File>imrx-20250924_lab.xml</File>
    <File>imrx-20250924_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm2526946d1_8k.htm">tm2526946d1_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm2526946d1_8k.htm": {
   "nsprefix": "IMRX",
   "nsuri": "http://immuneering.com/20250924",
   "dts": {
    "schema": {
     "local": [
      "imrx-20250924.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "imrx-20250924_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "imrx-20250924_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2526946d1_8k.htm"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 24
   },
   "report": {
    "R1": {
     "role": "http://immuneering.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-24",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2526946d1_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-09-24",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2526946d1_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://immuneering.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001104659-25-093436-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-25-093436-xbrl.zip
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M-*O5:CI#$9\^W^K/,W>YCN6 H/+,;IJ3AW-N?EVELM:; OP<<-0E<X )=<G
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M:3S'@4H6,<3V0U G(]U+0LA]31EJ3>B,)T>$LY"#IX8.495$3?J0W!>32X9
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MD.%P!$W'/!V85Q&M,[PEMT1P]RD$ZSG>3.6LIE)<#1&MAQ5<Z(,#,">XS:L
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M>+#$JW.7]-"/T5_G>K_YG1@R,]'DF8G=\'S$(,( 7.OPG,M*TQ69$,F'6 S
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M 7[*ACS>P5P<6;#L)*8E^9-&(3L<V/DI]):EF&>N'H/!O9XUO399G$@@W!U
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M$5 :\5.%/LHMKW"*A$EO=""M,HH20AGK-? D(&W1&S"3,"HP:M0?X[2V&/%
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MJ\P[-7*%W(\%@PRNTGH*T[:XV)ZSBT0[O(Y-1P2;CV@*?&S#22Z[]_,$I)F
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MCK&F5__ISJN_\^IO0;C,MF#&F6N=YN-/!_7"MGFSKF0N:S1<7:J*3%M0Y/G
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M,5Z3(R*U4(Y!)18.*J[(K3"Z]<))S7VBK[:0S.F#47E%16WNV/%SI\T4-"^
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M&!<W_QP6RUD73@7EDORH4K_0S6*,\QC>3"H3B9=/VA"R5'C?,.8G:HJMWS&
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M?__MZ&_T[W?G+U^:?]]Y9C?)I+K"1X_^;H]Z#/<D6I0P(?.WO_V ,WC?>]#
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M&HJ(2&\&TC>@542DDY(=U7<= AC\!_JKV"AFIK+FU]Q4\"],K(^9SO'O[)'
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M"X< AI$(;3:R;D5YBVE69RDC*<H!G97Y"L=FZ\,DWDB=&-4\4=%X7\41\:7
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MV:6_VK%_QD-_[?-?4$L! A0#%     @ [(HY6[HTU3@M P  ZPL  !$
M         ( !     &EM<G@M,C R-3 Y,C0N>'-D4$L! A0#%     @ [(HY
M6R#[UB3]"@  ?X8  !4              ( !7 ,  &EM<G@M,C R-3 Y,C1?
M;&%B+GAM;%!+ 0(4 Q0    ( .R*.5N'J<O77 <  -I7   5
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8=&U02P4&      8 !@"+ 0  0\@

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>tm2526946d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="imrx-20250924.xsd" xlink:type="simple"/>
    <context id="AsOf2025-09-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
        </entity>
        <period>
            <startDate>2025-09-24</startDate>
            <endDate>2025-09-24</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-09-24" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-09-24" id="Fact000004">0001790340</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-09-24" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-09-24" id="Fact000010">2025-09-24</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-09-24" id="Fact000011">Immuneering Corporation</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-09-24" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-09-24" id="Fact000013">001-40675</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-09-24" id="Fact000014">26-1976972</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-09-24" id="Fact000015">245 Main St.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2025-09-24" id="Fact000016">Second Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-09-24" id="Fact000017">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-09-24" id="Fact000018">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-09-24" id="Fact000019">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-09-24" id="Fact000020">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-09-24" id="Fact000021">500-8080</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-09-24" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-09-24" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-09-24" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-09-24" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-09-24" id="Fact000026">Class                                             A Common Stock,  par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-09-24" id="Fact000027">IMRX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-09-24" id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-09-24" id="Fact000029">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="AsOf2025-09-24" id="Fact000030">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
